0001144204-16-134253.txt : 20161114 0001144204-16-134253.hdr.sgml : 20161111 20161114163922 ACCESSION NUMBER: 0001144204-16-134253 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Neurotrope, Inc. CENTRAL INDEX KEY: 0001513856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463522381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55275 FILM NUMBER: 161995404 BUSINESS ADDRESS: STREET 1: 205 EAST 42ND STREET, STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (973) 242-0005 MAIL ADDRESS: STREET 1: 205 EAST 42ND STREET, STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: BlueFlash Communications, Inc. DATE OF NAME CHANGE: 20110223 10-Q 1 v452775_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to __________________

Commission File Number: 333-172647

Neurotrope, Inc.

(Exact name of registrant as specified in its charter)

Nevada	46-3522381
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

205 East 42^nd Street, 16^th Floor

New York, NY 10017

(973) 242-0005

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x

(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ¨ No x

As of November 10, 2016, there were 49,894,867 shares of the registrant’s common stock, $ 0.0001 par value per share, issued and outstanding.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan,” “anticipate,” “believe,” “estimate,” “should,” “expect” and similar expressions, include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission (the “SEC”). We advise you to carefully review the reports and documents we file from time to time with the SEC, particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to publicly release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

OTHER INFORMATION

When used in this report, the terms, “we,” the “Company,” “our,” and “us” refer to Neurotrope, Inc., a Nevada corporation (formerly BlueFlash Communications, Inc., a Florida corporation) and its consolidated subsidiary Neurotrope BioScience, Inc. (“Neurotrope BioScience”).

TABLE OF CONTENTS

		Page No.
PART I – FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2016 (Unaudited)	3
	Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (Unaudited)	3
	Condensed Consolidated Statements of Operations for the three months and nine months ended September 30, 2016 and 2015 (Unaudited)	4
	Condensed Consolidated Statement of Changes in Shareholders’ Deficit for the nine months ended September 30, 2016 (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (Unaudited)	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	26

Item 4.	Controls and Procedures.	26

Part II – OTHER INFORMATION

Item 1.	Legal Proceedings.	27

Item 1A.	Risk Factors.	27

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	27

Item 3.	Defaults Upon Senior Securities.	27

Item 4.	Mine Safety Disclosures.	27

Item 5.	Other Information.	27

Item 6.	Exhibits.	27

	Signatures.	28

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements.

Neurotrope, Inc and Subsidiary

Condensed Consolidated Balance Sheets

(Unaudited)

	September 30			December 31,
	2016			2015

ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	6,515,767		$	11,230,637
Prepaid expenses		209,348			1,489,851
Prepaid expenses - Related party		14,358			-
Subscription receivable		-			2,761

TOTAL CURRENT ASSETS		6,739,473			12,723,249

Fixed Assets, net of accumulated depreciation		56,934			59,175

TOTAL ASSETS	$	6,796,407		$	12,782,424

LIABILITIES AND SHAREHOLDERS' DEFICIT

CURRENT LIABILITIES
Accounts payable	$	1,401,177		$	449,875
Accrued expenses		199,233			141,525
Note payable		-			10,511
Accrued expenses - related party		352,624			389,058

TOTAL CURRENT LIABILITIES		1,953,034			990,969

Commitments and contingencies

Convertible redeemable preferred stock, Series B, $.0001 par value, 333,333 shares authorized; 256,927.4 issued and outstanding at September 30, 2016 and 262,349.4 shares issued and outstanding at December 31, 2015 Liquidation preference of $15,415,643 at September 30, 2016 and $15,740,963 at December 31, 2015. plus dividends accruable at 13.3% per annum of $1,816,973 as of September 30, 2016 and $279,824 as of December 31, 2015.		11,570,695			11,814,874

SHAREHOLDERS' DEFICIT
Common stock - 400,000,000 shares authorized, $.0001 par value; 49,739,796 issued and outstanding at September 30, 2016; 49,170,232 shares issued and outstanding at December 31, 2015		4,974			4,917
Additional paid-in capital		28,905,062			27,695,888
Accumulated deficit		(35,637,358	)		(27,724,224	)

TOTAL SHAREHOLDERS' DEFICIT		(6,727,322	)		(23,419	)

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$	6,796,407		$	12,782,424

See accompanying notes to condensed consolidated financial statements.

Neurotrope, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)

	Nine Months Ended			Nine Months Ended			Three Months Ended			Three Months Ended
	September 30			September 30			September 30			September 30
	2016			2015			2016			2015

OPERATING EXPENSES:
Research and development - related party	$	764,557		$	1,852,428		$	249,999		$	636,547
Research and development		3,548,608			1,348,143			1,729,929			268,665
General and administrative - related party		59,500			81,000			5,500			27,000
General and administrative		2,581,140			3,242,220			1,058,139			817,880
Stock-based compensation - related party		134,444			131,453			46,809			44,299
Stock-based compensation		830,335			255,774			503,283			97,913

TOTAL OPERATING EXPENSES		7,918,584			6,911,018			3,593,659			1,892,304

OTHER INCOME:
Interest income		5,450			2,844			1,516			355

Net loss before income taxes		(7,913,134	)		(6,908,174	)		(3,592,143	)		(1,891,949	)

Provision for income taxes		-			-			-			-

Net loss	$	(7,913,134	)	$	(6,908,174	)	$	(3,592,143	)	$	(1,891,949	)

Preferred Stock dividends		(1,537,149	)		(1,002,599	)		(512,397	)		(328,034	)

Net loss attributable to common shareholders	$	(9,450,283	)	$	(7,910,773	)	$	(4,104,540	)	$	(2,219,983	)

PER SHARE DATA:

Basic and diluted loss per common share	$	(0.19	)	$	(0.30	)	$	(0.08	)	$	(0.08	)

Basic and diluted weighted average common shares outstanding		49,295,000			26,214,000			49,678,000			27,801,000

See accompanying notes to condensed consolidated financial statements.

Neurotrope, Inc. and Subsidiary

Condensed Consolidated Statement of Changes in Shareholders’ Deficit

(Unaudited)

					Additional
	Common Stock				Paid-In		Accumulated
	Shares		Amount		Capital		Deficit			Total

Balance January 1, 2016		49,170,232	$	4,917	$	27,695,888	$	(27,724,224	)	$	(23,419	)

Conversion of Series B preferred stock to common stock		542,200		54		244,125		-			244,179

Stock based compensation		-		-		964,779		-			964,779

Exercise of common stock warrants		27,364		3		271		-			274

Net loss		-		-		-		(7,913,134	)		(7,913,134	)

Balance September 30, 2016		49,739,796	$	4,974	$	28,905,062	$	(35,637,358	)	$	(6,727,322	)

See accompanying notes to condensed consolidated financial statements.

Neurotrope, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended			Nine Months Ended
	September 30, 2016			September 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(7,913,134	)	$	(6,908,174	)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation		964,779			387,227
Depreciation expense		5,187			4,659
Change in assets and liabilities
Decrease (increase) in prepaid expenses		1,280,503			(250,858	)
(Increase) in prepaid expenses - related party		(14,358	)		-
Decrease in subscription receivable		2,761			-
(Decrease) in accrued expenses - related party		(36,434	)		36,547
Increase in accounts payable		951,302			231,970
Increase in accrued expenses		57,708			22,880
Total adjustments		3,211,448			432,425

Net Cash Used in Operating Activities		(4,701,686	)		(6,475,749	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(2,947	)		(11,827	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from note payable		-			28,904
Repayments on note payable		(10,511	)		(10,511	)
Proceeds from exercise of common stock warrants		274			2,363

Net Cash (Used in) Provided by Financing Activities		(10,237	)		20,756

NET DECREASE IN CASH		(4,714,870	)		(6,466,820	)

CASH AT BEGINNING OF PERIOD		11,230,637			8,010,357

CASH AT END OF PERIOD	$	6,515,767		$	1,543,537

DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:

Conversion of convertible redeemable preferred stock to common stock	$	244,179		$	4,002,153

See accompanying notes to condensed consolidated financial statements.

NEUROTROPE, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1 – Organization and Nature of Planned Business:

Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 6 below).

On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013, merged with and into Neurotrope BioScience (the “Reverse Merger”). Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock, par value $0.0001 per shares (the “Common Stock”) on a one-for-one basis.

The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date.

As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.”

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements included in this document have been prepared on the same basis as the annual consolidated financial statements, and in our opinion reflect all adjustments, which include normal recurring adjustments necessary for a fair presentation in accordance with GAAP and SEC regulations for interim financial statements. The results for the nine months ended September 30, 2016 are not necessarily indicative of the results that we will have for any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2015 included in our Annual Report on Form 10-K.

Note 2 – Going Concern:

The unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, we have generated no revenues to date, have incurred substantial losses and have substantial contractual commitments pursuant to various agreements to which we are a party.

Our ability to continue existence is dependent upon our continuing efforts to obtain additional financing to carry out our business plan. We intend to fund our operations through equity and/or debt financing arrangements and any revenues generated in the future. Any equity financing, if available, would most likely be significantly dilutive to our current stockholders. However, there can be no assurance that these arrangements, if any, will be sufficient to fund our ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time.

There can be no assurance that any additional financings will be available to us on satisfactory terms and conditions, if at all. These conditions raise substantial doubt as to our ability to continue as a going concern.

The consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

Note 3 – Summary of Significant Accounting Policies:

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents:

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2016, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation.

Property and Equipment:

Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following:

	September 30, 2016			December 31, 2015
Property and equipment	$	69,716		$	66,770
Accumulated depreciation		(12,782	)		(7,595	)
Property and equipment, net	$	56,934		$	59,175

Depreciation expense for the nine months ended September 30, 2016 and 2015 was $5,187 and $4,659, respectively.

Research and Development Costs:

All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2016 and December 31, 2015.

Income Taxes:

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions.

The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through September 30, 2016.

Risks and Uncertainties:

The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.

Stock Compensation:

The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense.

Options awarded to purchase shares of Common Stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.

Recent Accounting Pronouncements:

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to put most leases on their balance sheets by recognizing a lessee’s rights and obligations, while expenses will continue to be recognized in a similar manner to today’s legacy lease accounting guidance. This ASU could also significantly affect the financial ratios used for external reporting and other purposes, such as debt covenant compliance. This ASU will be effective for January 1, 2019, with early adoption permitted. We are currently in the process of assessing the impact of this ASU on our consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation (Topic 718), which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. We are currently in the process of assessing the impact of this ASU on our consolidated financial statements.

Note 4 – Contractual Commitments:

On September 4, 2014, the Company entered into a long-term lease for 4,000 square feet of office space in Newark, New Jersey. The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options. The base rent is payable, commencing December 1, 2014, at an annual rate of $88,000 with no increases during the lease term and renewal terms. In addition, commencing September 1, 2014, the Company is obligated to pay its share of common area charges. On May 1, 2016, the Company abandoned the lease and is negotiating with the landlord as to a settlement of amounts due. As of September 30, 2016, the Company has accrued the remainder of the lease payments for a total of approximately $136,100.

On August 4, 2016, the Company reached a settlement agreement (the “Settlement Agreement”) with Iroquois Master Fund Ltd. and certain of its affiliates (collectively, “Iroquois”) to settle a proposed consent solicitation pertaining to the reconstitution of the Company’s Board of Directors (the “Board”). Pursuant to the Settlement Agreement, in consideration for Iroquois agreeing to discontinue its proposed consent solicitation to reconstitute the Board: (i) Board members Paul Freiman and Jay Haft resigned from the Board of the Company, its subsidiaries and all committees thereof, effective immediately; (ii) the Company’s Chief Executive Officer, Charles Ramat, entered into a Separation Agreement with the Company (the “Ramat Separation Agreement”), pursuant to which he agreed to resign, without cause, from the Board and all other positions that he held with the Company, including Chief Executive Officer and President, on October 3, 2016 or such earlier date as determined by the Board, which date was later established by the Board as September 1, 2016 (the “Termination Date”) with Mr. Ramat remaining as a consultant to the Company until February 28, 2018; (iii) the Board appointed each of Mr. Joshua Silverman, former Principal and Managing Partner of Iroquois Capital Management, LLC, and Dr. Kenneth J. Gorelick, M.D. to the Board; and (iv) the Company entered into a consulting agreement with SM Capital Management, LLC, a limited liability company owned and controlled by Mr. Joshua Silverman.

Pursuant to the Ramat Separation Agreement, Mr. Ramat received his current salary and benefits through the Termination Date, except that his salary was reduced by $10,000 to $23,333 per month. On the Termination Date, Mr. Ramat received a lump sum severance payment in the amount of $200,000. The Ramat Separation Agreement further provided that (a) the consulting agreement between Ramat Consulting Group and the Company, effective February 28, 2013, was automatically restored and became fully effective and reinstated on the same terms and conditions for the balance of its five year term, which shall expire on February 28, 2018, and pursuant to which consulting fees are to be paid at the rate of $50,000 per annum, payable monthly, and (b) on the Termination Date, Mr. Ramat’s (i) outstanding unvested stock options, totaling 700,055, immediately vested, notwithstanding that Mr. Ramat, on the previously scheduled vesting dates, was no longer an employee, director, or service provider to the Company, and (ii) vested options (including those whose vesting occurs pursuant the preceding clause) shall continue to be exercisable for a period of ten (10) years following the respective dates of grant of such options.

In connection with the resignations of each of Mr. Freiman and Mr. Haft from the Board, the Company entered into a Director Separation Agreement, dated August 4, 2016, with each of Mr. Freiman and Mr. Haft (the “Director Separation Agreements”). Pursuant to such Director Separation Agreements, each of Mr. Freiman and Mr. Haft’s (i) outstanding unvested stock options, totaling 599,596 for both Mr. Freiman and Mr. Haft, immediately vested, notwithstanding that such director, on the previously scheduled vesting dates, will no longer be an employee, director, or service provider to the Company, and (ii) vested options (including those whose vesting occurs pursuant the preceding clause) shall continue to be exercisable for a period of ten (10) years following the respective dates of grant of such options.

In addition, on August 4, 2016, the Company entered into a consulting agreement with SM Capital Management, LLC (“SMCM”), a limited liability company owned and controlled by Mr. Joshua Silverman (the “Consulting Agreement”). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a one-year period, subject to annual review thereafter. SMCM’s annual consulting fee is $120,000, payable by the Company in monthly installments of $10,000. In addition, the Consulting Agreement provides that the Company shall take all actions within its control, including the recommendation of such director nominee by the Nominating and Governance Committee of the Board, to nominate and appoint one (1) additional member to the Board designated by Mr. Silverman during the initial consulting term.

The Company has entered into an employment agreement with the chief financial officer of the Company. The agreement for this officer has a remaining term as of September 30, 2016 extending through 2017, providing for an aggregate base salary of approximately $70,000 for the remainder of 2016 and approximately $210,000 for 2017.

Note 5 – Collaborative Agreements:

On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents.

During the nine months ended September 30, 2016, the Company paid Stanford the annual maintenance fee of $10,000 which will be amortized over the applicable one-year licensing period.

On May 15, 2014, the Company entered into an agreement with a contract research organization (“CRO”) to conduct a clinical trial relating to AD. The Company had agreed to pay fees to the CRO totaling $715,159, based upon signing of the agreement and the CRO achieving certain clinical trial milestones, plus reasonable out-of-pocket expenses. On November 19, 2014, the CRO agreement was amended, requiring the Company to pay a reduced amount totaling $657,238 plus third party pass-through expenses. On June 30, 2016, the Company paid $150,000 to fully settle its payable to the CRO and has no additional commitment pursuant to this agreement. The Company has incurred a total of $837,112 in fees.

On July 14, 2014, Neurotrope BioScience entered into an Exclusive License Agreement (the “Mount Sinai Agreement”) with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai Agreement, Mount Sinai granted Neurotrope BioScience a revenue-bearing, world-wide right and (a) exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (“PKCε”), which includes Niemann-Pick Disease (the “Mount Sinai Field of Use”). The Mount Sinai Agreement allows Neurotrope BioScience to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (“Mount Sinai Licensed Product(s)”) in the Mount Sinai Field of Use (as such terms are defined in the Mount Sinai Agreement). During the nine months ended September 30, 2016, the Company paid Mount Sinai $29,400, which represents 75% of total amounts due, for ongoing preclinical research and development work.

On October 9, 2015, Neurotrope BioScience executed a Services Agreement (the “Services Agreement”) with WCT, effective as of August 31, 2015. The Agreement relates to services for Neurotrope BioScience’s Phase 2 clinical study assessing the safety, tolerability and efficacy of bryostatin in the treatment of moderately severe to severe AD (the “Study”). Pursuant to the terms of the Services Agreement, WCT will provide services to enroll approximately one hundred and fifty (150) Study subjects. The first Study site was initiated during the fourth quarter of 2015. The total estimated budget for the services, including pass-through costs, was approximately $11.6 million. Neurotrope BioScience paid WCT an advance payment of $200,000 upon execution of the Services Agreement.

On November 11, 2015, Neurotrope BioScience paid WCT $1,875,861 for the following advance payment: (i) services fees of approximately $928,000; (ii) pass-through expenses of approximately $268,000; and (iii) investigator/institute fees of approximately $680,000. The remaining payments of approximately $9.5 million, before amendment as described below, were to be paid over the period from July 2016 through September 2017. Neurotrope BioScience may terminate the Agreement without cause upon 60 days’ prior written notice. As of September 30, 2016, the Company’s balance sheet includes a payable balance for WCT services of approximately $1.05 million. The Services Agreement can be terminated by the Company or WTC under certain terms, as described in the Services Agreement.

Also, in connection with the execution of the Services Agreement, Neurotrope BioScience received consent and entered into a Statement of Work pursuant to its CRE License Agreement (see Note 6 below).

Note 6 – Related Party Transactions and Licensing / Research Agreements:

One director of the Company, James Gottlieb, was also a director of CRE as of September 30, 2016. William Singer was the president of CRE until April 26, 2016. CRE is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 17.9% of the Company's outstanding Common Stock as of September 30, 2016.

Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement (the “TLSA”) with CRE, a related party, and NRV II, LLC (“NRV II”), another affiliate of CRE, which was amended by Amendment No. 1 to the TLSA as of August 21, 2013. As of February 4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the “CRE License Agreement”). The CRE License Agreement amended and restated the TLSA, as amended. Under the terms of the CRE License Agreement, CRE provides research services and has granted Neurotrope BioScience the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October 31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the “Field of Use”). Additionally, the TLSA specifies that all patents that issue from a certain patent application, shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain. After the initial Series A Stock financing, the CRE License Agreement required Neurotrope BioScience to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services.

In addition, the CRE License Agreement requires the Company to pay CRE a “Fixed Research Fee” of $1 million per year for five years, commencing on the date that the Company completes a Series B Preferred Stock financing resulting in proceeds of at least $25,000,000 (the “Series B Financing”). This Fixed Research Fee is not yet due. The CRE License Agreement also requires the payment of royalties ranging between 2% and 5% of the Company’s revenues generated from the licensed patents and other intellectual property, dependent upon the percentage ownership that NRVI holds in the Company. Under the CRE License Agreement, the Company was required to prepay royalty fees at a rate of 5% of all investor funds raised in the Series A or Series B Stock financings or any subsequent rounds of financing prior to a public offering, less commissions.

On November 12, 2015, Neurotrope BioScience, CRE, and NRV II entered into an amendment (the “Amendment”) to the TLSA pursuant to which CRE granted rights in certain technology to Neurotrope BioScience. Under the Amendment, the “Advances on Future Royalties” section of the TLSA was amended and restated to (i) eliminate the requirement that Neurotrope BioScience pay CRE prepaid royalties equal to five percent (5%) of financing proceeds received by Neurotrope BioScience in any financing prior to a public offering, and (ii) provide that Neurotrope BioScience will deliver to CRE, following each closing pursuant to a certain securities purchase agreement, an amount equal to 2.5% of the Post-PA Fees Proceeds received at such closing. In addition, the Amendment provides that on or prior to December 31, 2016, Neurotrope Bioscience shall deliver to CRE an amount equal to 2.5% of the aggregate Post-PA Fee Proceeds received at the closings. Each payment would constitute an advance royalty payment to CRE and will be offset (with no interest) against the amount of future royalty obligations payable until such time that the amount of such future royalty obligations equals in full the amount of the advance royalty payments made. “Post-PA Fee Proceeds” means the gross proceeds received, less all amounts paid to the placement agent(s), in relation to such gross proceeds. No other expenses of Neurotrope Bioscience shall be subtracted from the gross proceeds to determine the “Post-PA Fee Proceeds.” As of September 30, 2016, the Company recorded a liability of $348,011 resulting from this Amendment.

Pursuant to the CRE License Agreement, on February 4, 2015, Neurotrope BioScience and CRE entered into a new Statement of Work and Account Satisfaction Agreement (the “February 2015 SOW”). The February 2015 SOW was effective as of October 1, 2014 and ended on September 30, 2015. In consideration for the February 2015 SOW, CRE agreed to (a) use commercially reasonable efforts to enroll at least four (4) additional compassionate use or expanded access patients, in trials of CRE’s Alzheimer’s therapeutic drug platform during the term of the SOW, (b) perform certain services requested by Neurotrope BioScience for the further development of CRE’s Alzheimer’s therapeutic drug platform, (c) perform certain services for the further development of CRE’s Alzheimer’s diagnostic test, (d) to the extent permitted by applicable law, transfer all of its rights and regulatory obligations, except for those relating to the compassionate use expanded access trials, associated with CRE’s Investigative New Drug Application (“IND”) 71,276 to Neurotrope BioScience, (e) conduct initial research on the application of its PKCε platform to treat Fragile X disease, (f) conduct initial research on polyunsaturated fatty acid derivatives for the purpose of developing a commercially usable PKCε activator, and (g) provide assistance, advice and other similar services to Neurotrope BioScience regarding Neurotrope BioScience’s analysis of bryologs pursuant to Neurotrope BioScience’s agreement with Stanford University, for purpose of developing a commercially usable PKCε activator. Under the CRE License Agreement, Neurotrope BioScience received a license to certain technology, including rights relating to an in vitro test system based on examination of skin cells intended to predict the presence of AD in humans (the “AD Diagnostic Test”). Further, under the February 2015 SOW, Neurotrope BioScience’s rights to the technology associated with the AD Diagnostic Test automatically reverted to CRE based on certain contractual conditions on July 10, 2015 and, accordingly, Neurotrope Bioscience no longer has any rights under the CRE License Agreement for diagnostic applications using the CRE patent portfolio or technology. The remaining terms and conditions of the CRE License Agreement, including the license of technology associated with Neurotrope BioScience’s PKC activator research (such as bryostatin), remain in full force and effect, in accordance with the conditions thereof. For the year ended December 31, 2015, Neurotrope BioScience incurred $2,052,595 in expenses relating to the February 2015 SOW. The Company is obligated to pay CRE approximately $20,000 for ongoing testing and validation work, which should be completed by the fourth quarter of 2016.

On November 12, 2015, Neurotrope BioScience and CRE entered into a new statement of Work Agreement (the “November 2015 SOW Agreement”) pursuant to the TLSA. The November 2015 SOW Agreement is effective as of November 1, 2015 and continues until December 31, 2016. Pursuant to the November 2015 SOW Agreement, Neurotrope BioScience agreed to pay CRE $1,166,666 in service fees payable in the amount of e$83,333 per month for each month from November 1, 2015 through December 31, 2016. In consideration for the payments made pursuant to the November 2015 SOW Agreement, CRE shall perform the services requested by Neurotrope BioScience for the further development of Neurotrope’s bryostatin drug platform. During the nine months ended September 30, 2016, the Company paid CRE $750,000 pursuant to the November 2015 SOW Agreement, which is included in the statement of operations as Research and Development – Related Party.

On July 28, 2016, CRE filed a petition for Chapter 11 Reorganization in the United States Bankruptcy Court for the Northern District of West Virginia. As part of the bankruptcy filing, CRE asked the Bankruptcy Court to reject certain executory contracts including employment agreements with a number of its researchers and other personnel, including, without limitation, Dr. Daniel Alkon, who is our Chief Scientific Officer and was also the former scientific director of CRE, and who led a team of CRE scientists who are involved on behalf of CRE in support of the Neurotrope-CRE License Agreement. CRE has not requested that the Neurotrope-CRE License Agreement itself be rejected. We do not believe that CRE, as a matter of law, has a right to terminate the Neurotrope-CRE License Agreement as a result of the bankruptcy filing and have been advised by CRE’s representatives that there will be no action regarding the Neurotrope-CRE License and that CRE intends to meet all of its obligations in support of the Company’s work. On September 23, 2016, the United States Bankruptcy Court for the Northern District of West Virginia entered an order approving the sale of a substantial amount of CRE's assets to West Virginia University. The Court also entered an order approving a settlement agreement between Dr. Alkon, CRE and West Virginia University. As part of the asset sale, CRE sold the BRNI name and all derivatives to West Virginia University. Consequently, the Board of CRE resolved on September 28, 2016 to change its name to Cognitive Research Enterprises, Inc.

Note 7 – Income Taxes:

The Company incurred a net operating loss for income tax purposes of approximately $29,000,000 for the period from October 31, 2012 (inception) through September 30, 2016. The net operating loss carryforwards resulted in a deferred tax asset of approximately $10.5 million at September 30, 2016. Income tax effects of share-based payments are recognized in the financial statements for those awards that will normally result in tax deductions under existing tax law. Under current U.S. federal tax law, the Company would receive a compensation expense deduction related to non-qualified stock options only when those options are exercised. Accordingly, the financial statement recognition of compensation cost for non-qualified stock options creates a deductible temporary difference which results in a deferred tax asset of approximately $477,000 as of September 30, 2016. The Company does not recognize a tax benefit for compensation expense related to incentive stock options (“ISOs”) unless the underlying shares are disposed of in a disqualifying disposition. Accordingly, compensation expense related to ISOs is treated as a permanent difference for income tax purposes. These deferred tax assets are reduced to zero by an offsetting valuation allowance. As a result, there is no provision for income taxes.

Note 8 – Common Stock:

During the nine months ended September 30, 2016, three holders of 5,422 total shares of the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Stock”), converted those shares into 542,200 shares of Common Stock and three holders of 27,364 warrants exercisable at $0.01 per share of Common Stock exercised their warrants into 27,364 shares of Common Stock

On April 12, 2016, the stockholders of the Company approved to increase the number of authorized shares of our Common Stock to 400,000,000 shares.

Note 9 – Stock Options:

The Board adopted, with the approval of the Company’s stockholders, the 2013 Equity Incentive Plan (the “2013 Plan”), which provided for the issuance of incentive awards of up to 7,000,000 shares of Common Stock (until it was amended as provided below) to officers, key employees, consultants and directors.

On July 23, 2014, the Company’s Board approved an increase in the total number of shares available under the 2013 Plan by 3,000,000 to 10,000,000 shares. The increase was subsequently approved by the Company’s stockholders on June 9, 2015.

The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2016:

						Weighted-
						Average
				Weighted-		Remaining		Aggregate
				Average		Contractual		Intrinsic
	Number of			Exercise		Term		Value
	Shares			Price		(Years)		(in thousands)
Options outstanding at January 1, 2016		8,582,952		$	1.32		7.5	$	0
Options granted		1,400,000		$	0.60
Less options forfeited		(280,418	)	$	0.66
Less options expired/cancelled		(20,000	)	$	1.76
Less options exercised		-		$	-
Options outstanding at September 30, 2016		9,682,534		$	1.24		7.8	$	0
Options exercisable at September 30, 2016		7,516,318		$	1.36		7.2	$	0

In connection with the resignations of Mr. Ramat as President, Chief Executive Officer and director and of Mr. Freiman and Mr. Haft as directors, the Company entered into separation agreements, dated August 4, 2016, with each of Mr. Ramat, Mr. Freiman and Mr. Haft. Pursuant to such separation agreements, each of Mr. Ramat’s, Mr. Freiman’s and Mr. Haft’s (i) outstanding unvested stock options, totaling 1,296,329 in the aggregate, immediately vested and (ii) vested options shall continue to be exercisable for a period of ten (10) years following the respective dates of grant of such options (See Note 4 above.)

The following is a summary of stock options outstanding under the plans as of September 30, 2016:

							Stock Options
	Stock Options Outstanding						Exercisable
			Weighted Avg.		Weighted Avg.				Weighted Avg.
Range of	Number of		Contractual Life		Exercise		Number of		Exercise
Exercise Prices	Shares		(years)		Price		Shares		Price
$ 0.01 - $ 0.71		1,928,082		9.33	$	0.60		653,130	$	0.61
$ 0.80 - $ 1.00		3,062,048		7.76	$	0.93		2,397,551	$	0.92
$ 1.11 - $ 1.55		1,120,000		7.55	$	1.32		994,411	$	1.29
$ 1.64 - $ 2.22		3,572,404		7.08	$	1.82		3,471,226	$	1.82
		9,682,534		7.80	$	1.36		7,516,318	$	1.39

As of September 30, 2016, there were approximately $1.1 million of total unrecognized compensation costs related to unvested stock options and restricted stock. These costs are expected to be recognized over a weighted average period of 2.68 years.

The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method.

The fair value of stock options issued for the nine months ended September 30, 2016 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0%; Volatility 89.50%; Risk-free interest rate 1.60%; weighted average grant date fair value of $0.40 per share. There is no current allowance for forfeitures.

The total stock option-based compensation recorded as operating expense was $964,779 and $387,227 for the nine months ended September 30, 2016 and 2015, respectively. For the three months ending September 30, 2016, the totals were $550,092 and $142,212, respectively. All of the stock option-based compensation expense was classified as stock based compensation expense. On September 28, 2015, the Company’s Board amended the option agreements granted to all its officers and directors to clarify that the options were to be deemed non-qualified stock options.

Note 10 – Common and Preferred Stock Reserved for Future Issuances:

Common stock reserved for future issuances consisted of the following at September 30, 2016:

	Common Stock Reserved
Common stock warrants outstanding		134,800,876
Common stock for potential anti-dilution of warrants		66,712,722
Common stock options outstanding		9,682,534
Conversion of Series B Stock		25,692,740
Common stock for potential anti-dilution of Series B Stock		12,846,370
Total		249,735,242

On February 9, 2015, the holders of placement agent warrants to purchase an aggregate of 1,325,000 shares of our Series A Stock entered into Conversion Agreements with the Company pursuant to which such holders’ placement agent warrants to purchase Series A Stock were converted, for no additional consideration, into common stock purchase warrants to purchase an aggregate of 1,325,000 shares of Common Stock.

Resulting from the Company’s Series B private placement, the Company is required to reserve shares of Common Stock to accommodate up to an additional 50% issuable upon potential dilution to the Series B Stock and each the series A, series B, series C, series D and series E Warrants issued in the Series B private placement plus the placement agent warrants issued as fees relating to the Series B private placement.

Note 11 – Subsequent Events:

From October 1, 2016 through November 11, 2016, two holders of the Company’s Series B Stock converted a total of 1,477 shares of the Company’s Series B Stock into 144,700 shares of Common Stock.

From October 1, 2016 through November 11, 2016, three holders of 7,371 warrants exercisable at $0.01 per share of Common Stock exercised their warrants into 7,371 shares of Common Stock.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this report and our annual report filed on Form 10-K for the year ended December 31, 2015.

Basis of Presentation

The unaudited financial statements for our fiscal quarters ended September 30, 2016 and 2015 include a summary of our significant accounting policies and should be read in conjunction with the discussion below and our financial statements and related notes included elsewhere in this quarterly report.

Overview

Neurotrope BioScience was founded as a Delaware corporation in October 2012. Our activities since Neurotrope BioScience’s inception through September 30, 2016 have been devoted primarily to the research and development of AD therapeutic products using patented technology and raising capital. This technology is licensed by us from Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), and its affiliate, NRV II, LLC (“NRV II”) pursuant to the Amended and Restated Technology License and Services Agreement (“CRE License”), entered into on February 4, 2015 and amended on November 12, 2015. Prior to being licensed to us, the technology had been under development by CRE since 1999 and was financed by CRE from a variety of non-investor sources including not-for-profit foundations, the National Institutes of Health and individual philanthropists up until March 2013. From March 2013 forward, development of the licensed technology has been funded principally through collaboration by CRE with Neurotrope BioScience. See the description of Neurotrope BioScience financings below in “Financial Condition, Liquidity and Capital Resources – Sources and Uses of Liquidity.” The Company has not realized any revenues from its operations.

Pursuant to the CRE License, Neurotrope BioScience maintained its exclusive (except as described below), non-transferable (except pursuant to the CRE License’s assignment provision), world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II, LLC by CRE as of or subsequent to October 31, 2012 to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the “Field of Use”). Additionally, the CRE License specifies that all patents that issue from a certain patent application, shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. Furthermore, on July 10, 2015 under the terms of the Statement of Work and Account Satisfaction Agreement dated February 4, 2015, Neurotrope BioScience’s rights relating to an in vitro diagnostic test system reverted to CRE and, accordingly, Neurotrope Bioscience no longer has any rights under the CRE License for diagnostic applications using the CRE patent portfolio or technology.

Notwithstanding the above license terms, CRE and its affiliates retain rights to use the licensed intellectual property in the Field of Use to engage in research and development and other non-commercial activities and to provide services to Neurotrope BioScience or to perform other activities in connection with the CRE License.

Under the CRE License, CRE is a preferred service provider in certain circumstances and Neurotrope BioScience may not enter into sublicense agreements with third parties except with CRE’s prior written consent, which consent shall not be commercially unreasonably withheld. Furthermore, the CRE License dated February 4, 2015 revises the agreement that was entered into as of October 31, 2012 and amended on August 21, 2013, in that it provides that any intellectual property developed, conceived or created in connection with a sublicense agreement that Neurotrope BioScience entered into with a third party pursuant to the terms of the CRE License will be licensed to CRE and its affiliates for any and all non-commercial purposes, on a worldwide, perpetual, non-exclusive, irrevocable, non-terminable, fully paid-up, royalty-free, transferable basis, with the right to freely sublicense such intellectual property. Previously, the agreement had provided that such intellectual property would be assigned to CRE.

Under the CRE License, CRE and Neurotrope BioScience will jointly own data, reports and information that is generated on or after February 28, 2013, by Neurotrope BioScience, on behalf of Neurotrope BioScience by a third party or by CRE pursuant to a statement of work that the parties enter into pursuant to the CRE License, in each case to the extent not constituting or containing any data, reports or information generated prior to such date or by CRE not pursuant to a statement of work (the “Jointly Owned Data”). CRE has agreed not to use the Jointly Owned Data inside or outside the Field of Use for any commercial purpose during the term of the CRE License or following any expiration of the CRE License other than an expiration that is the result of a breach by Neurotrope BioScience of the CRE License that caused any licensed patent to expire, become abandoned or be declared unenforceable or invalid or caused any licensed technology to enter the public domain (a “Natural Expiration”), provided, however, CRE may use the Jointly Owned Data inside or outside the Field of Use for any commercial purpose following any termination of the CRE License. Also, CRE granted Neurotrope BioScience a license during the term and following any Natural Expiration, to use certain CRE data in the Field of Use for any commercial purposes falling within the scope of the license granted to Neurotrope BioScience under the CRE License.

The CRE License further requires us to pay CRE (i) a fixed research fee equal to a pro rata amount of $1 million in the year during which we close on a Series B Preferred Stock financing resulting in proceeds of at least $25 million, (ii) a fixed research fee of $1 million per year for each of the five calendar years following the completion of such financing and (iii) an annual fixed research fee in an amount to be negotiated and agreed upon no later than 90 days prior to the end of the fifth calendar year following the completion of such financing to be paid with respect to each remaining calendar year during the term of the CRE License. This fixed research fee is not yet due.

On November 12, 2015, we entered into an amendment to the CRE License. Pursuant to the amendment, we paid an aggregate of approximately $348,000 to CRE following the closings of the Series B private placement, which constituted an advance royalty payment to CRE and will be offset (with no interest) against the amount of future royalty obligations payable until such time that the amount of such future royalty obligations equals in full the amount of the advance royalty payments made.

The term of the CRE License continues until the later of the date (i) the last of the licensed patents expires, is abandoned or is declared unenforceable or invalid (in each case, determined in accordance with the CRE License) and (ii) the last of the licensed technology enters the public domain. Either party has the right to terminate the CRE License after 30 days prior notice in certain circumstances, including if either party were to materially breach any provisions of the CRE License and does not cure such material breach within 60-days from notice of such material breach from the non-breaching party, and for breaches that are capable of being cured, in the event of certain bankruptcy or insolvency proceedings.

Concurrently with the November 12, 2015 amendment to the CRE License, Neurotrope Bioscience entered into a new Statement of Work Agreement pursuant to the CRE License Agreement (the “November 2015 SOW Agreement”). The November 2015 SOW Agreement replaced the February 2015 SOW Agreement, which was effective as of October 1, 2014 and expired on September 30, 2015.

Pursuant to the November 2015 SOW Agreement, Neurotrope Bioscience agreed to pay CRE one million one hundred sixty-six thousand six hundred sixty-six dollars ($1,166,666) in service fees payable in the amount of eighty-three thousand three hundred thirty-three dollars ($83,333) per month for each month from November 1, 2015 through December 31, 2016. The payments under the November 2015 SOW Agreement will satisfy Neurotrope Bioscience’s obligations to reimburse CRE pursuant to Section 5.6 of the CRE License for any and all attorneys’ fees, translation costs, filing fees, maintenance fees, and other costs and expenses related to applying for, filing, prosecuting, and maintaining patents and applications for the licensed intellectual property incurred by CRE during the term of the November 2015 SOW Agreement (but, for the avoidance of doubt, such payments shall not satisfy any attorneys’ fees, translation costs, filing fees, maintenance fees, or other costs or expenses related to applying for, filing, prosecuting, and maintaining patents and applications for the licensed intellectual property incurred by CRE after the expiration or termination of the November 2015 SOW Agreement term), as well as any litigation costs which CRE may incur related to any of the licensed intellectual property during the November 2015 SOW Agreement term. CRE shall not commence any litigation to enforce the licensed intellectual property without the consent of Neurotrope Bioscience (which consent shall not be unreasonably withheld, delayed, or denied).

In consideration for the payments made pursuant to the November 2015 SOW Agreement, CRE shall perform the services requested by Neurotrope Bioscience for the further development of Neurotrope’s bryostatin drug platform. In addition, under the terms of the November 2015 SOW Agreement, CRE may enroll one additional compassionate use, in addition to the compassionate use patient (who has currently completed a compassionate use trial) in trials of CRE’s Alzheimer’s therapeutic drug platform during the November 2015 SOW Agreement term, and the payments set forth above, shall satisfy any and all of Neurotrope Bioscience’s obligation whatsoever to CRE or to any other third party for costs incurred or to be incurred by CRE relating to such trials. Neurotrope Bioscience and CRE shall jointly review protocols which shall be established to the parties’ mutual satisfaction and contain appropriate safety measures to be employed by the treating physician. No additional compassionate use or expanded access patients will be enrolled by CRE without the consent of Neurotrope Bioscience.

On July 28, 2016, CRE filed a petition for Chapter 11 Reorganization in the United States Bankruptcy Court for the Northern District of West Virginia. As part of the bankruptcy filing, CRE asked the Bankruptcy Court to reject certain executory contracts including employment agreements with a number of its researchers and other personnel, including, without limitation, Dr. Daniel Alkon, who is our President and Chief Scientific Officer and was also the former scientific director of CRE, and who led a team of CRE scientists who are principally involved on behalf of CRE in support of the Neurotrope-CRE License Agreement. CRE has not requested that the Neurotrope-CRE License Agreement itself be rejected. We do not believe that CRE, as a matter of law, has a right to terminate the CRE License Agreement as a result of the bankruptcy filing and have been advised by CRE’s representatives that there will be no action regarding the Neurotrope-CRE license and that CRE intends to meet all of its obligations in support of the Company’s work. On September 23, 2016, the United States Bankruptcy Court for the Northern District of West Virginia entered an order approving the sale of a substantial amount of CRE's assets to West Virginia University. The Court also entered an order approving a settlement agreement between Dr. Alkon, CRE and West Virginia University. As part of the asset sale, CRE sold the Blanchette Rockefeller Neurosciences Institute, or BRNI, name and all derivatives to West Virginia University. Consequently, the Board of CRE resolved on September 28, 2016 to change its name to Cognitive Research Enterprises, Inc.

On May 12, 2014, we entered into a license agreement (the “Stanford Agreement”), with The Board of Trustees of the Leland Stanford Junior University (“Stanford”) pursuant to which Stanford granted us a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. Pursuant to the Stanford Agreement, we paid a $60,000 license initiation fee to Stanford. We currently pay Stanford a $10,000 annual license maintenance fee, and will pay milestone payments in the aggregate amount of up to $3,700,000 upon the achievement of certain product development events commencing upon the filing of the first IND application through approval of an applicable product, as well as low single-digit royalties on net sales of the licensed products. Each party has the right to terminate the Stanford Agreement for an uncured material breach of the other party. Additionally, we may terminate the Stanford Agreement at any time upon 60 days written notice to Stanford.

On July 29, 2014, we announced that we initiated our Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with AD. The trial was being conducted under an IND application filed by CRE. CRE transferred its rights and obligations arising under such IND application to us on February 4, 2015. We enrolled a total of nine patients in the randomized, double-blind, placebo-controlled, single dose study. Six patients were randomized to receive bryostatin by injection and three received a matching placebo control. The primary objective of the clinical trial was to assess the safety and tolerability of a single dose of bryostatin in the treatment of patients with AD. The secondary objectives of the study were the preliminary evaluation of the efficacy of a single dose of bryostatin in the treatment of patients with AD, its pharmacokinetics and pharmacodynamics and the evaluation of any correlation between changes in PKCε with plasma levels of bryostatin and with improvement in cognitive function. On February 24, 2015, we announced that the Phase 2a clinical trial met its primary endpoint demonstrating preliminary safety and tolerability of bryostatin. On March 17, 2015, we announced that preliminary assessment of PKCε levels in peripheral monocytes demonstrated a significant increase in total PKC protein levels at the end of the bryostatin infusion consistent with target engagement. An additional secondary objective of the study was the evaluation of efficacy following a single dose of bryostatin and there was no measurable improvement in cognition in this mildly impaired patient population.

Following on these results, on October 9, 2015, Neurotrope BioScience executed a Services Agreement with Worldwide Clinical Trials, Inc. (“WCT”), effective as of August 31, 2015. The Services Agreement relates to services for Neurotrope BioScience’s Phase 2 clinical study assessing the safety, tolerability and efficacy of bryostatin in the treatment of moderately severe to severe AD, or the Study. Pursuant to the terms of the Services Agreement, WCT will provide services to enroll approximately one hundred and fifty (150) study subjects at approximately 30 sites across the United States. We began enrollment at the initial sites at the end of 2015. Assuming prompt enrollment at the majority of the sites, we expect that within approximately 15 months, we will receive data from an interim analysis with final top line results available in approximately 18 months from the start of enrollment. This trial was designed to administer dosing of bryostatin for up to six months for moderately severe to severe AD patients but has been amended to administer dosing of bryostatin for up to three months (see details of the amendment below). Among the trial’s endpoints are the measurement of improvement in cognition, activities of daily living and behavior. The Company’s goal is to show the robust treatment effect that the regulatory agencies, the marketplace and, most importantly, our patients and their caregivers are seeking.

On July 27, 2016, we received approval of the institutional review board (“IRB”) for our amended protocol submitted on July 21, 2016 to the U.S. Food and Drug Administration (the “FDA”) relating to the Phase 2 clinical trial of our lead drug candidate, Bryostatin-1, for the treatment of advanced AD, which amended protocol eliminates the second, exploratory, study period following the first 12 weeks of treatment. The primary objective is the assessment of safety and tolerability of bryostatin to occur at 13 weeks and that has not been changed with this amendment. The secondary objective is to assess efficacy, also at week 13. Such amendment, to cut the exploratory part of the study, was made for business reasons in order to provide earlier completion of the study and for the planning of future studies. The changes to the study design were not due to any safety concerns. In the study, two doses of bryostatin, 20μg or 40μg, will be compared to placebo. Study subjects receive a total of 7 doses of the study drug over 12 weeks of treatment, followed by safety and efficacy assessments at week 13 and a final study visit at week 16. There will be no second randomization for additional treatment. Subjects who have already entered into the second study period will be discontinued and evaluated 30 days following last treatment for their final study visit. Pending the robustness of trial enrollment, we expect to report data late in the first quarter or the beginning of the second quarter of 2017.

The total estimated budget for the services, including pass-through costs, was approximately $11.6 million before the amendment of its Phase 2 clinical study protocol as outlined above. As a result of the amendment, the Company believes that the total trial cost will be reduced. Neurotrope BioScience may terminate the Services Agreement without cause upon sixty (60) days’ prior written notice. As of September 30, 2016, Neurotrope BioScience has paid WCT approximately $3.7 million for current and future services.

Strategy

Our strategy is to efficiently utilize our licensed proprietary and patented technologies to further the development of those technologies toward commercializing a therapeutic for AD and potentially utilize these technologies to treat other neurological diseases. We may also seek to acquire, by license or otherwise, other development stage products that are consistent with our product portfolio objectives and commercialization strategy. In addition, we plan to utilize technologies licensed from CRE and Mount Sinai in order to pursue therapeutics for orphan drug indications, including Fragile X Syndrome and Niemann-Pick Type C disease. Through an agreement with CRE, we have the exclusive worldwide license relating to Fragile X Syndrome (“FXS”). FXS is the most common cause of inherited intellectual disability and the most common known genetic cause of autism or autism spectrum disorders. Symptoms of FXS include a range from learning disabilities to more severe cognitive or intellectual disabilities. Delays in speech and language development are common, as are a variety of physical and behavioral characteristics. FXS is caused by a “full mutation” of the FMR1 Gene. There are approximately 135,000 Fragile X Syndrome patients in the United States and a similar number in Europe. Neurotrope BioScience received support from the FRAXA Research Foundation, Inc. (“FRAXA”) to fund a pre-clinical FXS behavior study for bryostatin at FRAXA’s sponsored laboratory located at the University of Chile in Santiago, Chile. FRAXA provided full funding for a preclinical study to evaluate the behavioral effects of bryostatin-1 in an FXS mouse model. Twice weekly treatment for 13 weeks yielded statistically significant improvements in outcome measures with bryostatin compared to placebo. We have formed and are advancing our discussions with an experienced clinical advisory board to assist us with protocol development for a planned Phase 2a study in FXS patients. We seek resources to initiate the first clinical trial with bryostatin in patients with FXS. We have been granted orphan drug designation by the FDA for the use of bryostatin in the treatment of Fragile X Syndrome.

Use of bryostatin to treat a serious and deadly lysosomal storage disorder, Niemann-Pick Type C Disease (“NP-C”), is being explored by the Company in collaboration with the Icahn School of Medicine at Mount Sinai in New York City. NP-C mainly affects children who develop severe neurologic symptoms including gait disturbance and cognitive deficits early in life. There are approximately 3,500 NP-C patients in the United States and a similar number in Europe. Patients with NP-C have a gene defect that results in the loss of the “normal” NPC1 or NPC2 protein that is important for cholesterol trafficking.

A study was funded by several family foundations under the auspices of SOAR-NPC. This study examined the effects of various dosing regimens of bryostatin in NP-C mice over a brief treatment period. Although bryostatin showed mixed results in vivo, the SOAR study did not find encouraging results with its in vivo animal model. Another in vivo study began at the beginning of 2016 and is currently underway at Mt. Sinai to evaluate the effect of bryostatin in an animal model (NPC1 mice) of Niemann-Pick Type C. Depending upon the in vivo results and available funding, we will work towards completion of the necessary pre-clinical work in order to file and obtain FDA approval of an IND, or investigational new drug application. We are encouraged by preliminary data.in the NPC1 animal model. Assuming that the pre-clinical work shows positive activity, we expect to apply for orphan drug designation for this indication.

Neurotrope has entered into a research collaboration with the International Rett Syndrome Foundation (“Foundation”), under the Rett Syndrome.org Scout Program, funded by the Foundation, whereby bryostatin will be tested using mouse models. The hope is that bryostatin will activate key synaptic growth factors that are deficient in patients suffering from Rett Syndrome.

The Company is also advancing its drug development program thru a licensing agreement with Stanford regarding the synthesis of brylogs and related technology.

Going Concern

As shown in the consolidated financial statements contained in this report, we have generated no revenues to date, have incurred substantial losses, and have substantial contractual commitments pursuant to various agreements to which we are a party including costs associated with our ongoing Phase 2 clinical trial and related amendments to the clinical trial protocol.

The unaudited condensed consolidated financial statements contained in this report do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

Critical Accounting Policies, Estimates, and Judgments

Our financial statements are prepared in accordance with accounting principles that are generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to accounting for equity compensation and our commitments to strategic alliance partners and the timing of the achievement of collaboration milestones. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent assets and liabilities. These estimates and judgments are also based on historical experience and other factors that are believed to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known, even for estimates and judgments that are not deemed critical.

Comparison of the nine months ended September 30, 2016 and September 30, 2015

Revenues

We did not generate any revenues for the nine months ended September 30, 2016 and 2015.

Operating Expenses

Overview

Total operating expenses for the nine months ended September 30, 2016 were $7,918,584 as compared to $6,911,018 for the nine months ended September 30, 2015, an increase of approximately 15%. The increase in operating expenses is due primarily to the increase in research and development associated primary with our ongoing Phase 2 clinical trial in AD and non-cash stock compensation expenses, partially offset by the decrease in related party research and development and general and administrative expenses.

Research and Development Expenses

For the nine months ended September 30, 2016, we incurred $764,557 of research and development – related party as compared to $1,852,428 for the nine months ended September 30, 2015. These expenses consisted primarily of a flat fee of $83,333 per month as compared to $200,000 per month for the nine months ended September 30, 2016 versus 2015, respectively, plus $14,557 as compared to $52,428 for expenses relating to the Company’s therapeutic activities for the nine months ended September 30, 2016 and 2015, respectively. These fees and expenses are incurred pursuant to our strategic alliance with CRE for ongoing research and development principally relating to the development of our potential therapeutic products. The change in monthly expense is pursuant to the November 2015 SOW, which covered product development activities and maintenance of the licensed patent portfolio.

For the nine months ended September 30, 2016, we incurred $3,548,608 in research and development expenses with non-related parties as compared to $1,348,143 for the nine months ended September 30, 2015. These expenses were incurred pursuant to developing the potential AD therapeutic product, specifically conducting the Phase 2 clinical trial for AD and products relating to orphan drug indications. Of these expenses, for the nine months ended September 30, 2016, $3,410,398 related to conducting our AD Phase 2 clinical trial and related storing of drug product, $63,670 for clinical consulting services, $16,939 of licensing payment amortization relating to the Stanford and Mount Sinai license agreements, $37,600 for orphan drug development costs and $20,000 for development of alternative drug supply with Stanford University as compared to, for the nine months ended September 30, 2015, $1,108,509 related to conducting our AD Phase 2a clinical trial and related storing of drug product, $156,072 for clinical consulting services, $41,078 of licensing payment amortization relating to the Stanford and Mount Sinai license agreements, $30,484 for orphan drug development costs and $12,000 for development of alternative drug supply with Stanford University.

General and Administrative Expenses

We incurred related party general and administrative expenses totaling $59,500 for the nine months ended September 30, 2016 as compared to $81,000 for the nine months ended September 30, 2015. These amounts are attributable to the payments to our prior Chairman for services provided to us which ended in July 2016.

We incurred $2,581,140 and $3,242,220 of other general and administrative expenses for the nine months ended September 30, 2016 and 2015, respectively, a decrease of approximately 20%. Of the amounts for the nine months ended September 30, 2016 as compared to the comparable 2015 period: $1,330,679 was incurred primarily for wages, vacation pay, taxes and insurance, for four employees plus our Chairman and our Chief Executive Officer, versus $2,017,166 for five employees plus our Chairman for the 2015 comparable period; $464,344 versus $597,096 for ongoing legal expenses as the Company had significant contractual negotiations for the prior nine month period, $116,755 was incurred for outside operations consulting services versus $0 as the Company hired a consultant to help recruit our new Chief Medical Officer during the current nine month period; $82,659 was incurred for travel expenses, versus $117,090; $161,103 was incurred for investor relations services versus $171,736; $107,587 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services versus $98,023; $133,025 was incurred for insurance versus $177,800, and; $204,988 was incurred for office rent, including acceleration of expense based upon abandonment of approximately $120,000, and utilities, supplies, license fees, filing costs, rent, advertising and other, versus $143,806, which is offset by a credit of $80,497 relating to a settlement of a payable to a service provider for the comparable 2015 period. As further discussed in Note 4 (Contractual Commitments) that are included in the Notes to Condensed Consolidated Financial Statements (Unaudited) above, with respect to the amounts that we incurred for severance, we accrued a total of $265,000 of severance payments as of September 30, 2015, which was contingent upon the Company raising additional capital in excess of $7.5 million. The capital raise was completed in November 2015.

Stock Based Compensation Expenses

We incurred related party non-cash expenses totaling $134,444 as compared to $131,453 for the nine months ended September 30, 2016 and 2015, respectively, in connection with the vesting of stock options.

We incurred $830,335 and $255,774 of non-related party non-cash expenses for issuance of stock options for the nine months ended September 30, 2016 and 2015, respectively. The increase is a result of the issuance of stock options during the fourth quarter of 2015 and the first nine months of 2016 and the acceleration of options vesting for two of the Company’s former board members and former President and Chief Executive Officer as discussed in Note 4 (Contractual Commitments) that are included in the Notes to Condensed Consolidated Financial Statements (Unaudited) above.

Other Income

We earned $5,450 of interest income for the nine months ended September 30, 2016 as compared to $2,844 for the nine months ended September 30, 2015 on funds temporarily deposited in an interest bearing money market account. This increase is attributable to the Company’s capital raising activities in November 2015 offset by the reduction in cash balances.

Net losses and earnings per share

We incurred losses of $7,913,134 and $6,908,174 for the nine months ended September 30, 2016 and 2015, respectively. The increased loss was primarily due to our increase in expenses associated with our current Phase 2 clinical trial and an increase in stock-based compensation expense, offset by a decrease in related-party research and development expenses and lower general and administrative expenses. Earnings (losses) per common share were ($0.19) and ($0.30) for the nine months ended September 30, 2016 and 2015, respectively. The decrease in loss per share is primarily attributable to the increased weighted average common shares outstanding partially offset by an increase in accrued preferred stock dividends.

Comparison of the three months ended September 30, 2016 and September 30, 2015

Revenues

We did not generate any revenues for the three months ended September 30, 2016 and 2015.

Operating Expenses

Overview

Total operating expenses for the three months ended September 30, 2016 were $3,593,659 as compared to $1,892,304 for the three months ended September 30, 2015, an increase of approximately 90%. The increase in operating expenses is due primarily to the increase in research and development associated primary with our ongoing Phase 2 clinical trial in AD, a slight increase in general and administrative expenses and an increase in non-cash stock compensation expenses, partially offset by the decrease in related party research and development expenses.

Research and Development Expenses

For the three months ended September 30, 2016, we incurred $249,999 of research and development expenses – related party as compared to $636,547 for the three months ended September 30, 2015. These expenses consisted primarily of a flat fee of $83,333 per month as compared to $200,000 per month for the three months ended September 30, 2016 versus 2015, respectively, plus $0 as compared to $20,666 for expenses relating to the Company’s therapeutic activities for the three months ended September 30, 2016 and 2015, respectively. These fees and expenses are incurred pursuant to our strategic alliance with CRE for ongoing research and development principally relating to the development of our potential therapeutic products. The change in monthly expense / flat fee is pursuant to the November 2015 SOW, which covered product development activities and maintenance of the licensed patent portfolio.

For the three months ended September 30, 2016, we incurred $1,729,929 in research and development expenses with non-related parties as compared to $268,665 for the three months ended September 30, 2015. These expenses were incurred pursuant to the development of the potential AD therapeutic product and related Phase 2 clinical trial and products relating to orphan drug indications. Of these expenses, for the three months ended September 30, 2016, $1,682,602 related to conducting our AD Phase 2 clinical trial and related storing of drug product, $30,304 for clinical consulting services, $3,022 of licensing payment amortization relating to the Stanford and Mount Sinai license agreements, $6,000 for orphan drug development costs and $8,000 for development of alternative drug supply with Stanford University as compared to, for the three months ended September 30, 2015, $235,724 related to conducting our AD Phase 2a clinical trial and related storing of drug product, $17,331 for clinical consulting services, $7,341 of licensing payment amortization relating to the Stanford and Mount Sinai license agreements, $12,469 for orphan drug development costs and ($4,200) for development of alternative drug supply with Stanford University. The credit relates to a reclassification and capitalization of licensing fees paid during the first half of 2015.

General and Administrative Expenses

We incurred related party general and administrative expenses totaling $5,500 and $27,000 for the three months ended September 30, 2016 and 2015, respectively. These amounts are attributable to the payments to our prior Chairman for services provided to us which ended in July 2016.

We incurred $1,058,139 and $817,880 of other general and administrative expenses for the three months ended September 30, 2016 and 2015, respectively, an increase of approximately 29%. Of the amounts for the three months ended September 30, 2016 versus the comparable 2015 period: $606,802 was primarily incurred for wages, vacation pay, taxes and insurance, for four employees plus our Chairman and our Chief Executive Officer, versus $506,818 for five employees plus our Chairman for the 2015 comparable period; $252,781 versus $200,796 for ongoing legal expenses; $26,072 was incurred for travel expenses, versus $35,061; $49,230 was incurred for investor relations services versus $43,616; $23,475 was incurred for professional fees associated with auditing, financial, accounting and tax advisory services versus $22,521; $47,744 was incurred for insurance versus $51,051; and $7,280 was incurred for office supplies, license fees, filing costs, advertising and other, versus $38,514 which includes office rent and utilities not included for the comparable 2016 period and which is offset by a credit of $80,497 relating to a settlement of a payable to a service provider for the comparable 2015 period.

Stock Based Compensation Expenses

We incurred related party non-cash expenses totaling $46,809 versus $44,299 for the three months ended September 30, 2016 and 2015, respectively, in connection with the vesting of stock options.

We incurred $503,283 and $97,913 of non-related party non-cash expenses for issuance of stock options for the three months ended September 30, 2016 and 2015, respectively. The increase is primarily attributable to acceleration of options vesting for two of the Company’s former board members and former President and Chief Executive Officer as discussed in Note 4 (Contractual Commitments) that are included in the Notes to Condensed Consolidated Financial Statements (Unaudited) above.

Other Income

We earned $1,516 of interest income for the three months ended September 30, 2016 as compared to $355 for the three months ended September 30, 2015, on funds temporarily deposited in an interest bearing money market account. This increase is attributable to the Company’s capital raising activities in November 2015 offset by the reduction in cash balances.

Net losses and earnings per share

We incurred losses of $3,592,143 and $1,891,949 for the three months ended September 30, 2016 and 2015, respectively. The increased loss was primarily attributable to our increase in expenses associated with our current Phase 2 clinical trial, a slight increase in other general and administrative expenses and an increase in stock-based compensation expense, offset by a decrease in related-party research and development expenses. Losses per common share were ($0.08) for the three months ended September 30, 2016 and 2015. The flat loss per share is primarily attributable to the increased weighted average common shares outstanding and a reduction in our loss from operations, partially offset by an increase in accrued preferred stock dividends.

Financial Condition, Liquidity and Capital Resources

Since the inception of Neurotrope BioScience, we have primarily devoted our efforts to the development of our therapeutic products, raising capital, negotiating the CRE License and, until June 30, 2015, the license we formerly held under the CRE License Agreement to certain technology, including rights relating to an in vitro test system based on examination of skin cells intended to predict the presence of AD in humans (the “AD Diagnostic Test”) toward commercialization while conducting business planning and recruiting executive management.

Cash and Working Capital

Since inception, we have incurred negative cash flows from operations. As of September 30, 2016, we had an accumulated deficit of $35,637,358 and had working capital of $4,786,439 as compared to working capital of $11,732,280 as of December 31, 2015. The $6,945,841 decrease in working capital was primarily attributable to expenditures relating to development of a potential therapeutic product and general and administrative expenses, which resulted in a net loss of $7,913,134 plus capital expenditures of $2,947 for the nine months ended September 30, 2016.

Sources and Uses of Liquidity

Since inception, we have satisfied our operating cash requirements from the private placement of equity securities sold principally to outside investors. We expect to continue to incur expenses, resulting in losses and negative cash flows from operations, over at least the next several years as we continue to develop AD therapeutic products. We anticipate that this development will include continuing our current clinical trials as well as new clinical trials and additional research and development expenditures.

We expect to require additional capital in order to initiate, pursue and complete all planned clinical trials and development of bryostatin. Additional funding may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed, we may not be able to initiate, pursue and complete all planned clinical trials or continue the development of our product candidates or we could be required to delay, scale back or eliminate some or all of our development programs and operations. Any additional equity financing, if available, may not be available on favorable terms, would most likely be significantly dilutive to our current stockholders and debt financing, if available, may involve restrictive covenants. If we are able to access funds through collaborative or licensing arrangements, we may be required to relinquish rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize on our own, on terms that are not favorable to us. Our ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm our business, financial condition and results of operations.

We currently have approximately $5.9 million in cash and cash equivalents, which we expect to be sufficient to fund our operations for approximately the next three months. This cash will be used, for the next three months, for corporate overhead of approximately $1.3 million and $4.4 million for the continuing AD clinical trial. We expect to raise additional capital to fund our ongoing clinical trial and corporate overhead.

Off-Balance Sheet Arrangements

We did not engage in any “off-balance sheet arrangements” (as that term is defined in Item 303(a)(4)(ii) of Regulation S-K) as of September 30, 2016.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable to a smaller reporting company.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive officer and principal financial officer, respectively, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are not effective due to the material weakness resulting from a limited segregation of duties among our employees with respect to our control activities. This deficiency is the result of our limited number of employees. This deficiency may affect management’s ability to determine if errors or inappropriate actions have taken place. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible changes in our disclosure controls and procedures.

Management has implemented certain measures including additional cash controls, dual-signature procedures, and other review and approval processes by the Company’s management team. The Company intends to hire additional personnel to allow for improved financial reporting controls and segregation of duties when the Company’s operations and revenues have grown to the point of warranting such controls.

Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business, financial condition or results of operation. There are currently no pending legal proceedings that we believe will have individually or in the aggregate, a material adverse effect on our business, financial condition or operating results. As far as we are aware, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject.

Item 1A. Risk Factors.

An investment in shares of our common stock is highly speculative and involves a high degree of risk. We face a variety of risks that may affect our operations and financial results and many of those risks are driven by factors that we cannot control or predict. Before investing in our common stock you should carefully consider the following risks, together with the financial and other information contained in this report. If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be materially adversely affected. In that case, the trading price of our common stock would likely decline and you may lose all or a part of your investment. Only those investors who can bear the risk of loss of their entire investment should invest in our common stock.

There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the period ended December 31, 2015 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. For a further discussion of our Risk Factors, refer to the “Risk Factors” discussion contained in our Annual Report on Form 10-K and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

There have been no other unregistered sales of equity securities during the quarter ended September 30, 2016.

Item 3. Defaults upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Not applicable.

Item 6. Exhibits.

Exhibit
Number		Description

31.1*		Certification of the President and Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*		The following financial information from this Quarterly Report on Form 10-Q for the period ended September 30, 2016, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations; (ii) the Condensed Consolidated Balance Sheets; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Consolidated Financial Statements, tagged as blocks of text.

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Neurotrope, Inc.

Date: November 14, 2016	By:	/s/ Susanne Wilke, Ph.D.
		Susanne Wilke, Ph.D.
		Chief Executive Officer

Date: November 14, 2016	By:	/s/ Robert Weinstein
		Robert Weinstein
		Chief Financial Officer, Executive Vice President, Secretary and Treasurer

Exhibit Index

Exhibit
Number		Description

31.1*		Certification of the President and Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*		The following financial information from this Quarterly Report on Form 10-Q for the period ended September 30, 2016, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations; (ii) the Condensed Consolidated Balance Sheets; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Consolidated Financial Statements, tagged as blocks of text.

* Filed herewith.

EX-31.1 2 v452775_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

SUSANNE WILKE, PH.D.

CHIEF EXECUTIVE OFFICER

NEUROTROPE, INC.

I, Susanne Wilke, Ph.D., Chief Executive Officer of Neurotrope, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Neurotrope, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2016

		/s/ Susanne Wilke, Ph.D.
		Susanne Wilke, Ph.D.
		Chief Executive Officer

EX-31.2 3 v452775_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

ROBERT WEINSTEIN

CHIEF FINANCIAL OFFICER

NEUROTROPE, INC.

I, Robert Weinstein, Chief Financial Officer of Neurotrope, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Neurotrope, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2016

	/s/ Robert Weinstein
	Robert Weinstein
	Chief Financial Officer, Executive Vice President, Secretary and Treasurer

EX-32.1 4 v452775_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Neurotrope, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Susanne Wilke, Ph.D., Chief Executive Officer of the Company, state and certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2016

	/s/ Susanne Wilke, Ph.D.
	Susanne Wilke, Ph.D.
	Chief Executive Officer

EX-32.2 5 v452775_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Neurotrope, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Weinstein, Chief Financial Officer of the Company, state and certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2016

	/s/ Robert Weinstein
	Robert Weinstein
	Chief Financial Officer, Executive Vice President, Secretary and Treasurer

EX-101.INS 6 ntrp-20160930.xml XBRL INSTANCE DOCUMENT 0001513856 2015-01-01 2015-09-30 0001513856 2015-01-01 2015-12-31 0001513856 2016-01-01 2016-09-30 0001513856 2016-04-12 0001513856 2015-07-01 2015-09-30 0001513856 2016-07-01 2016-09-30 0001513856 2014-09-04 0001513856 2016-09-30 0001513856 2015-10-01 2015-10-09 0001513856 2015-10-09 0001513856 2012-10-31 2016-09-30 0001513856 2015-11-01 2015-11-11 0001513856 2016-11-10 0001513856 2015-12-31 0001513856 2015-09-30 0001513856 2014-12-31 0001513856 ntrp:SeriesBConvertibleRedeemablePreferredStockMember 2016-09-30 0001513856 ntrp:SeriesBConvertibleRedeemablePreferredStockMember 2015-12-31 0001513856 us-gaap:CommonStockMember 2015-12-31 0001513856 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001513856 us-gaap:RetainedEarningsMember 2015-12-31 0001513856 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001513856 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001513856 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001513856 us-gaap:CommonStockMember 2016-09-30 0001513856 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001513856 us-gaap:RetainedEarningsMember 2016-09-30 0001513856 ntrp:ContractResearchOrganizationMember 2014-05-01 2014-05-15 0001513856 ntrp:ContractResearchOrganizationMember 2014-11-02 2014-11-19 0001513856 ntrp:ContractResearchOrganizationMember 2016-06-01 2016-06-30 0001513856 ntrp:StanfordAgreementMember 2016-01-01 2016-09-30 0001513856 ntrp:MountSinaiAgreementMember 2016-01-01 2016-09-30 0001513856 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001513856 ntrp:January2016ThroughSeptember2017Member 2015-11-11 0001513856 ntrp:WorldwideClinicalTrialsMember 2016-09-30 0001513856 us-gaap:SeriesBPreferredStockMember ntrp:FixedResearchFeeMember 2016-01-01 2016-09-30 0001513856 us-gaap:PresidentMember 2016-09-30 0001513856 ntrp:ServicesReimbursementMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001513856 ntrp:ServicesReimbursementMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001513856 ntrp:ServicesReimbursementMember 2016-01-01 2016-09-30 0001513856 ntrp:BlanchetteRockefellerNeurosciencesInstituteMember 2015-10-27 2015-11-12 0001513856 ntrp:BlanchetteRockefellerNeurosciencesInstituteMember 2016-09-30 0001513856 ntrp:BrniLicenseAgreementMember 2015-11-12 0001513856 ntrp:BrniLicenseAgreementMember 2015-10-27 2015-11-12 0001513856 ntrp:BrniLicenseAgreementMember 2016-09-30 0001513856 ntrp:NeurotropeIncMember us-gaap:CommonStockMember 2016-09-30 0001513856 ntrp:NeurotropeIncMember us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001513856 ntrp:SeriesBConvertiblePreferredStockMember 2016-01-01 2016-09-30 0001513856 ntrp:SeriesBConvertiblePreferredStockMember 2016-09-30 0001513856 ntrp:EquityIncentivePlan2013Member 2016-09-30 0001513856 ntrp:EquityIncentivePlan2013Member us-gaap:MinimumMember 2014-07-23 0001513856 ntrp:EquityIncentivePlan2013Member us-gaap:MaximumMember 2014-07-23 0001513856 ntrp:ExercisePriceRangeOneMember 2016-09-30 0001513856 ntrp:ExercisePriceRangeTwoMember 2016-09-30 0001513856 ntrp:ExercisePriceRangeThreeMember 2016-09-30 0001513856 ntrp:ExercisePriceRangeFourMember 2016-09-30 0001513856 ntrp:ExercisePriceRangeOneMember 2016-01-01 2016-09-30 0001513856 ntrp:ExercisePriceRangeTwoMember 2016-01-01 2016-09-30 0001513856 ntrp:ExercisePriceRangeThreeMember 2016-01-01 2016-09-30 0001513856 ntrp:ExercisePriceRangeFourMember 2016-01-01 2016-09-30 0001513856 ntrp:CommonStockWarrantOutstandingMember 2016-09-30 0001513856 ntrp:CommonStockForPotentialAntidilutionOfWarrantsMember 2016-09-30 0001513856 ntrp:CommonStockOptionOutstandingMember 2016-09-30 0001513856 ntrp:ConversionOfSeriesBStockMember 2016-09-30 0001513856 ntrp:CommonStockForPotentialAntidilutionOfSeriesBStockMember 2016-09-30 0001513856 us-gaap:SeriesAPreferredStockMember ntrp:WarrantHolderMember 2015-02-01 2015-02-09 0001513856 ntrp:WarrantHolderMember 2015-02-01 2015-02-09 0001513856 us-gaap:SubsequentEventMember 2016-10-01 2016-11-11 0001513856 us-gaap:SubsequentEventMember 2016-11-11 0001513856 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2016-10-01 2016-11-11 0001513856 ntrp:SeriesBConvertibleRedeemablePreferredStockMember 2016-01-01 2016-09-30 0001513856 ntrp:SeriesBConvertibleRedeemablePreferredStockMember 2015-01-01 2015-12-31 0001513856 ntrp:SeparationAgreementsMember us-gaap:ManagementMember 2016-08-04 0001513856 ntrp:SeparationAgreementsMember us-gaap:ManagementMember 2016-07-07 2016-08-04 0001513856 ntrp:EmploymentAgreementsMember 2016-09-30 0001513856 ntrp:FixedResearchFeeMember 2016-01-01 2016-09-30 0001513856 ntrp:CreMember 2016-01-01 2016-09-30 0001513856 us-gaap:ChiefExecutiveOfficerMember 2016-08-31 0001513856 us-gaap:ChiefExecutiveOfficerMember 2016-08-01 2016-08-31 0001513856 us-gaap:ManagementMember 2016-08-31 0001513856 us-gaap:ManagementMember 2016-08-01 2016-08-31 0001513856 ntrp:SmCapitalManagementLlcMember 2016-08-31 0001513856 ntrp:November2015SowAgreementMember 2016-01-01 2016-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:sqft xbrli:pure

6515767

11230637

209348

1489851

6739473

12723249

56934

59175

6796407

12782424

1401177

449875

199233

141525

10511

352624

389058

1953034

990969

4974

4917

28905062

27695888

-35637358

-27724224

-6727322

-23419

6796407

12782424

2761

11570695

11814874

764557 1852428

3548608

1348143

59500 81000

2581140

3242220

134444 131453

830335

255774

7918584

6911018

5450

2844

-7913134

-6908174

-7913134

-6908174

1537149

1002599

-9450283

-7910773

-0.19

-0.30

26214000

49295000

249999 636547

1729929

268665

5500 27000

1058139

817880

46809 44299

503283

97913

3593659

1892304

1516

355

-3592143

-1891949

-3592143

-1891949

512397

328034

-4104540

-2219983

-0.08

27801000

49678000

4917

27695888

-27724224

49170232

244179

244125

542200

964779

4974

28905062

-35637358

49739796

274 3 271 27364

-7913134

964779

5187

-1280503

387227

4659

250858

951302

231970

57708

22880

3211448

432425

-4701686

-6475749

2947

11827

274

2363

-10237

20756

-4714870

-6466820

4002153

244179

10511

1543537

8010357

-2761 0

-36434

36547

28904

69716

12782

66770

7595

88000

4000

136100

715159 657238

837112

10000 29400 0.75 11600000

200000

150000

1875861

928000 268000 680000 9500000

1050000

25000000

0.179

0.02 0.05 0.05 0.05 0.025

348011

2052595

1166666

83333

20000

477000

29000000

10500000

542200

27364

0.01

27364

5422

0.0001

400000000

7000000

3000000

10000000

8582952

1400000

280418

9682534

7516318

1.32

0.60

0.66

1.24

1.36

20000

1.76

P7Y9M18D

P7Y6M

P7Y2M12D

1928082

3062048

1120000

3572404

P9Y3M29D

P7Y9M4D

P7Y6M18D

P7Y29D

0.6

0.93

1.32

1.82

653130

2397551

994411

3471226

0.61

0.92

1.29

1.82

1100000

P2Y8M5D

0.8950

0.0160

0.40

550092

142212

249735242

134800876

66712722

9682534

25692740

12846370

1325000

0.5

1325000

10-Q false 2016-09-30 2016 Q3 Neurotrope, Inc. 0001513856 --12-31 Smaller Reporting Company NTRP 49894867

0.0001

400000000

49739796

49170232

0.0001

333333

256927.4

262349.4

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Common</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Common stock warrants outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>134,800,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Common stock for potential anti-dilution of warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>66,712,722</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Common stock options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,682,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Conversion of Series B Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,692,740</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Common stock for potential anti-dilution of Series B Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,846,370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>249,735,242</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1477

144700

0.01

7371

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><u><font style="FONT-SIZE: 10pt">Note 9  Stock Options</font></u></strong><strong><font style="FONT-SIZE: 10pt">:</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The Board adopted, with the approval of the Company’s stockholders, the 2013 Equity Incentive Plan (the “2013 Plan”), which provided for the issuance of incentive awards of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,000,000</font> shares of Common Stock (until it was amended as provided below) to officers, key employees, consultants and directors. </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">On July 23, 2014, the Company’s Board approved an increase in the total number of shares available under the 2013 Plan by <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> shares. The increase was subsequently approved by the Company’s stockholders on June 9, 2015.</font></div> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options outstanding at January 1, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,582,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,400,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less options forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(280,418)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less options expired/cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options outstanding at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9,682,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options exercisable at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>7,516,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In connection with the resignations of Mr. Ramat as President, Chief Executive Officer and director and of Mr. Freiman and Mr. Haft as directors, the Company entered into separation agreements, dated August 4, 2016, with each of Mr. Ramat, Mr. Freiman and Mr. Haft. Pursuant to such separation agreements, each of Mr. Ramat’s, Mr. Freiman’s and Mr. Haft’s (i) outstanding unvested stock options, totaling <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,296,329</font> in the aggregate, immediately vested and (ii) vested options shall continue to be exercisable for a period of ten (10) years following the respective dates of grant of such options (See Note 4 above.)</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of stock options outstanding under the plans as of September 30, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Stock Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Stock Options Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div>Range of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div>Exercise Prices</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>(years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="29%"> <div>$ 0.01 - $ 0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,928,082</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>653,130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>$ 0.80 - $ 1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,062,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,397,551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>$ 1.11 - $ 1.55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,120,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>994,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>$ 1.64 - $ 2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,572,404</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,471,226</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9,682,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>7,516,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 35pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2016, there were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.1</font> million of total unrecognized compensation costs related to unvested stock options and restricted stock. These costs are expected to be recognized over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.68</font> years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The fair value of stock options issued for the nine months ended September 30, 2016 was estimated at the grant date using the following weighted average assumptions: Dividend yield <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0</font>%; Volatility <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 89.50</font>%; Risk-free interest rate <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.60</font>%; weighted average grant date fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.40</font> per share. There is no current allowance for forfeitures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The total stock option-based compensation recorded as operating expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">964,779</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">387,227</font> for the nine months ended September 30, 2016 and 2015, respectively. For the three months ending September 30, 2016, the totals were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">550,092</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">142,212</font>, respectively. All of the stock option-based compensation expense was classified as stock based compensation expense. On September 28, 2015, the Company’s Board amended the option agreements granted to all its officers and directors to clarify that the options were to be deemed non-qualified stock options. </font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="3"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options outstanding at January 1, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,582,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,400,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less options forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(280,418)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less options expired/cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options outstanding at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9,682,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Options exercisable at September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>7,516,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following is a summary of stock options outstanding under the plans as of September 30, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Stock Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Stock Options Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div>Range of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%"> <div>Exercise Prices</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>(years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="29%"> <div>$ 0.01 - $ 0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,928,082</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>653,130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>$ 0.80 - $ 1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,062,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,397,551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>$ 1.11 - $ 1.55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,120,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>994,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div>$ 1.64 - $ 2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,572,404</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,471,226</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9,682,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>7,516,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.01

0.71

0.80

1.00

1.11

1.55

1.64

2.22

14358

15415643

15740963

0.133

1296329

1816973

279824

P10Y

14358

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><u><font style="FONT-SIZE: 10pt">Note 1  Organization and Nature of Planned Business</font></u></b><b><font style="FONT-SIZE: 10pt">:</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 6 below).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><b><i><font style="FONT-SIZE: 10pt">  </font></i></b></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013, merged with and into Neurotrope BioScience (the “Reverse Merger”). Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per shares (the “Common Stock”) on a one-for-one basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.”</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements included in this document have been prepared on the same basis as the annual consolidated financial statements, and in our opinion reflect all adjustments, which include normal recurring adjustments necessary for a fair presentation in accordance with GAAP and SEC regulations for interim financial statements. The results for the nine months ended September 30, 2016 are not necessarily indicative of the results that we will have for any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2015 included in our Annual Report on Form 10-K.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in" align="justify"><strong><font style="FONT-SIZE: 10pt">Property and Equipment:</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>69,716</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>66,770</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(12,782)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,595)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>56,934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>59,175</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">Depreciation expense for the nine months ended September 30, 2016 and 2015 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,187</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,659</font>, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Research and Development Costs:</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2016 and December 31, 2015.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Stock Compensation:</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">    </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Options awarded to purchase shares of Common Stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>69,716</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>66,770</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(12,782)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,595)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>56,934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>59,175</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

70000

210000

1000000

348011

200000

50000

700055

P10Y

599596

P10Y

120000

10000

The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options.

750000

EX-101.SCH 7 ntrp-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Deficit link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Nature of Planned Business: link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Going Concern: link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Summary of Significant Accounting Policies: link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Contractual Commitments: link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Collaborative Agreements: link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Related Party Transactions and Licensing / Research Agreements: link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Income Taxes: link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Common Stock: link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stock Options: link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Subsequent Events: link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Summary of Significant Accounting Policies: (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies: (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Stock Options: (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Organization and Nature of Planned Business: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Summary of Significant Accounting Policies: (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Summary of Significant Accounting Policies: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Contractual Commitments: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Collaborative Agreements: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Related Party Transactions and Licensing / Research Agreements: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Income Taxes: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Common Stock: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Stock Options: (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Stock Options: (Details 1) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Stock Options: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Subsequent Events: (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 ntrp-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ntrp-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ntrp-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract] Significant Accounting Policies [Text Block] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] STOCKHOLDERS' EQUITY [Abstract] Stockholders Equity Note Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] Stock Option Note Disclosure [Text Block] The entire disclosure for stock option note disclosure. Common And Preferred Stock Reserved For Future Issuances [Abstract] Common And Preferred Stock Reserved For Future Issuances [Text Block] The entire disclosure for common and preferred stock reserved for future issuances. Subsequent Events [Abstract] Subsequent Events [Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD Prepaid Expense, Current, Total Prepaid expenses Due from Related Parties, Current Prepaid expenses - Related party Property, Plant and Equipment, Net Fixed Assets, net of accumulated depreciation Property and equipment, net Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' DEFICIT Liabilities, Current [Abstract] CURRENT LIABILITIES Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Notes Payable, Current, Total Note payable Commitments and Contingencies Commitments and contingencies Common Stock, Value, Issued Common stock - 400,000,000 shares authorized, $.0001 par value; 49,739,796 issued and outstanding at September 30, 2016; 49,170,232 shares issued and outstanding at December 31, 2015 Additional Paid in Capital, Total Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders Equity Attributable to Parent, Total TOTAL SHAREHOLDERS' DEFICIT Balance Balance Temporary Equity [Abstract] CONVERTIBLE REDEEMABLE PREFERRED STOCK Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Guarantor Obligations [Table Text Block] Schedule of Related Party Transactions, by Related Party [Table] Title of Individual [Axis] Relationship to Entity [Domain] President [Member] Series B Preferred Stock [Member] Transaction Type [Axis] Transaction [Domain] Services Reimbursement [Member] Range [Axis] Range [Domain] Minimum [Member] Maximum [Member] Nature of Expense [Axis] Interim Period, Costs Not Allocable [Domain] Fixed Research Fee [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Scenario [Axis] Equity Method Investment, Ownership Percentage Proceeds from Issuance of Preferred Stock and Preference Stock Technology Services Costs Research and Development Expense, Total Research and development Royalties Percentage This element represents the payment percentage on royalties pursuant with revenues generation from licensed patents and other intellectual properties. Income Tax Expenses Benefit [Table] Income Tax Expenses Benefit [Line Items] Operating Income (Loss) Deferred Tax Assets, Gross, Current Schedule of Stock by Class [Table] Related Party [Axis] Related Party [Domain] Legal Entity [Axis] Entity [Domain] Neurotrope Inc. [Member] Statement Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock, Shares Authorized Common stock, shares authorized Conversion of Stock, Shares Converted Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Option Indexed to Issuers Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Number of Shares, Options outstanding Number of Shares, Options outstanding Stock Options Outstanding, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of Shares, Options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of Shares, Less options forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Number of Shares, Less options expired/cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of Shares, Less options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Number of Shares, Options exercisable Stock Options Exercisable, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Weighted-Average Exercise Price, Options outstanding Weighted Avg. Exercise Price Weighted-Average Exercise Price, Options outstanding Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Less options forfeited Award Type [Axis] Equity Award [Domain] Equity Incentive Plan 2013 [Member] Plan Name [Axis] Plan Name [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Temporary Equity, Par or Stated Value Per Share Convertible redeemable preferred stock, par value (in dollars per share) Temporary Equity, Shares Authorized Convertible redeemable preferred stock, shares authorized Temporary Equity, Shares Issued Convertible redeemable preferred stock, shares issued Temporary Equity, Shares Outstanding Convertible redeemable preferred stock, shares outstanding Temporary Equity, Liquidation Preference Convertible redeemable preferred stock, Liquidation Preference, Value (in dollars) Preferred Stock, Dividend Rate, Percentage Dividends Payable Percentage (in percentage) Common Stock Warrant Outstanding [Member] Common stock warrants outstanding [Member] Common stock for potential anti-dilution of warrants [Member] Class of Stock [Line Items] Common Stock, Capital Shares Reserved for Future Issuance Common Stock Reserved Subsequent Event [Table] Subsequent Event [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Income Statement [Abstract] Operating Expenses [Abstract] OPERATING EXPENSES: Research And Development Related Party Research and development - related party Research and development expenses of related party. General And Administrative Expense Related Party General and administrative - related party The aggregate total of expenses of managing and administering the affairs of relate party. General and Administrative Expense, Total General and administrative Stock based compensation-related party Stock-based compensation - related party The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation to related parties . As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Other Income and Expenses [Abstract] OTHER INCOME: Interest Income, Other Interest income Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total Net loss before income taxes Income Tax Expense (Benefit) Provision for income taxes Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Preferred Stock Dividends and Other Adjustments Preferred Stock dividends Earnings Per Share, Basic and Diluted, Total Basic and diluted loss per common share Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted weighted average common shares outstanding Statement of Stockholders Equity [Abstract] Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated Deficit [Member] Shares, Outstanding, Beginning Balance Balance (in shares) Balance (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of Series B preferred stock to common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of Series B preferred stock to common stock (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock based compensation Stock Issued During Period, Value, Warrants Exercised Exercise of common stock warrants Value of stock issued as a result of the exercise of warrants. Stock Issued During Period Shares, Warrant Exercises Exercise of common stock warrants (in shares) Number of shares of capital stock issued during the current period as a result of warrants exercised. STATEMENT OF CASH FLOW [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used by operating activities Employee Benefits and Share-based Compensation Stock based compensation Increase (Decrease) in Operating Capital [Abstract] Change in assets and liabilities Increase (Decrease) in Prepaid Expense Decrease (increase) in prepaid expenses Increase (Decrease) in Due from Related Parties, Current (Increase) in prepaid expenses - related party Increase Decrease In Subscription Receivable Decrease in subscription receivable The increase (decrease) during the reporting period in the total amount of receivables from subscription. Increase (Decrease) in Due to Related Parties, Total (Decrease) in accrued expenses - related party Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total Net Cash Used in Operating Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from Notes Payable Proceeds from note payable Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total Net Cash (Used in) Provided by Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) NET DECREASE IN CASH Conversion of Stock, Shares Issued Conversion of convertible redeemable preferred stock to common stock GENERAL ORGANIZATION AND BUSINESS [Abstract] Nature of Operations [Text Block] Nature of Operations [Text Block] Contractual Commitments [Abstract] Contractual Commitments [Text Block] The entire disclosure of contractual commitments related to the company. Assets, Total TOTAL ASSETS Depreciation, Depletion and Amortization Depreciation expense Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] DISCLOSURE OF NON-CASH FINANCING ACTIVITIES: Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Disclosures: Sale of Stock [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Less options expired/cancelled Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Less options exercised Other Commitments [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1 Concentration Risk, Credit Risk, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross Property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Scenario, Unspecified [Domain] Collaborative Agreements [Abstract] Collaborative Agreements [Text Block] The entire disclosure for collaborative agreements. Collaborative Agreements [Table] License Initiation Fee Represents the license initiation fee paid during the period. Annual License Maintenance Fee Represents the amount of annual license maintenance fee paid during reporting period Stanford Agreement [Member] EX-101.PRE 11 ntrp-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 logo_10q.jpg GRAPHIC begin 644 logo_10q.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Nov. 10, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	Neurotrope, Inc.
Entity Central Index Key	0001513856
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NTRP
Entity Common Stock, Shares Outstanding		49,894,867

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 6,515,767	$ 11,230,637
Prepaid expenses	209,348	1,489,851
Prepaid expenses - Related party	14,358	0
Subscription receivable	0	2,761
TOTAL CURRENT ASSETS	6,739,473	12,723,249
Fixed Assets, net of accumulated depreciation	56,934	59,175
TOTAL ASSETS	6,796,407	12,782,424
CURRENT LIABILITIES
Accounts payable	1,401,177	449,875
Accrued expenses	199,233	141,525
Note payable	0	10,511
Accrued expenses - related party	352,624	389,058
TOTAL CURRENT LIABILITIES	1,953,034	990,969
Commitments and contingencies
SHAREHOLDERS' DEFICIT
Common stock - 400,000,000 shares authorized, $.0001 par value; 49,739,796 issued and outstanding at September 30, 2016; 49,170,232 shares issued and outstanding at December 31, 2015	4,974	4,917
Additional paid-in capital	28,905,062	27,695,888
Accumulated deficit	(35,637,358)	(27,724,224)
TOTAL SHAREHOLDERS' DEFICIT	(6,727,322)	(23,419)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	6,796,407	12,782,424
Series B Convertible Redeemable Preferred Stock [Member]
CONVERTIBLE REDEEMABLE PREFERRED STOCK
Convertible redeemable preferred stock, Series B, $.0001 par value, 333,333 shares authorized; 256,927.4 issued and outstanding at September 30, 2016 and 262,349.4 shares issued and outstanding at December 31, 2015 Liquidation preference of $15,415,643 at September 30, 2016 and $15,740,963 at December 31, 2015. plus dividends accruable at 13.3% per annum of $1,816,973 as of September 30, 2016 and $279,824 as of December 31, 2015.	$ 11,570,695	$ 11,814,874

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	49,739,796	49,170,232
Common stock, shares outstanding	49,739,796	49,170,232
Series B Convertible Redeemable Preferred Stock [Member]
Convertible redeemable preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible redeemable preferred stock, shares authorized	333,333	333,333
Convertible redeemable preferred stock, shares issued	256,927.4	262,349.4
Convertible redeemable preferred stock, shares outstanding	256,927.4	262,349.4
Convertible redeemable preferred stock, Liquidation Preference, Value (in dollars)	$ 15,415,643	$ 15,740,963
Dividends Payable Percentage (in percentage)	13.30%	13.30%
Dividends Payable (in dollars)	$ 1,816,973	$ 279,824

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
OPERATING EXPENSES:
Research and development - related party	$ 249,999	$ 636,547	$ 764,557	$ 1,852,428
Research and development	1,729,929	268,665	3,548,608	1,348,143
General and administrative - related party	5,500	27,000	59,500	81,000
General and administrative	1,058,139	817,880	2,581,140	3,242,220
Stock-based compensation - related party	46,809	44,299	134,444	131,453
Stock-based compensation	503,283	97,913	830,335	255,774
TOTAL OPERATING EXPENSES	3,593,659	1,892,304	7,918,584	6,911,018
OTHER INCOME:
Interest income	1,516	355	5,450	2,844
Net loss before income taxes	(3,592,143)	(1,891,949)	(7,913,134)	(6,908,174)
Provision for income taxes	0	0	0	0
Net loss	(3,592,143)	(1,891,949)	(7,913,134)	(6,908,174)
Preferred Stock dividends	(512,397)	(328,034)	(1,537,149)	(1,002,599)
Net loss attributable to common shareholders	$ (4,104,540)	$ (2,219,983)	$ (9,450,283)	$ (7,910,773)
PER SHARE DATA:
Basic and diluted loss per common share	$ (0.08)	$ (0.08)	$ (0.19)	$ (0.30)
Basic and diluted weighted average common shares outstanding	49,678,000	27,801,000	49,295,000	26,214,000

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Changes in Shareholders' Deficit - 9 months ended Sep. 30, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ (23,419)	$ 4,917	$ 27,695,888	$ (27,724,224)
Balance (in shares) at Dec. 31, 2015		49,170,232
Conversion of Series B preferred stock to common stock	244,179	$ 54	244,125	0
Conversion of Series B preferred stock to common stock (in shares)		542,200
Stock based compensation	964,779	$ 0	964,779	0
Exercise of common stock warrants	274	$ 3	271	0
Exercise of common stock warrants (in shares)		27,364
Net loss	(7,913,134)	$ 0	0	(7,913,134)
Balance at Sep. 30, 2016	$ (6,727,322)	$ 4,974	$ 28,905,062	$ (35,637,358)
Balance (in shares) at Sep. 30, 2016		49,739,796

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,913,134)	$ (6,908,174)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	964,779	387,227
Depreciation expense	5,187	4,659
Change in assets and liabilities
Decrease (increase) in prepaid expenses	1,280,503	(250,858)
(Increase) in prepaid expenses - related party	(14,358)	0
Decrease in subscription receivable	2,761	0
(Decrease) in accrued expenses - related party	(36,434)	36,547
Increase in accounts payable	951,302	231,970
Increase in accrued expenses	57,708	22,880
Total adjustments	3,211,448	432,425
Net Cash Used in Operating Activities	(4,701,686)	(6,475,749)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(2,947)	(11,827)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from note payable	0	28,904
Repayments on note payable	(10,511)	(10,511)
Proceeds from exercise of common stock warrants	274	2,363
Net Cash (Used in) Provided by Financing Activities	(10,237)	20,756
NET DECREASE IN CASH	(4,714,870)	(6,466,820)
CASH AT BEGINNING OF PERIOD	11,230,637	8,010,357
CASH AT END OF PERIOD	$ 6,515,767	$ 1,543,537
DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Conversion of convertible redeemable preferred stock to common stock	244,179	4,002,153

XML 19 R7.htm IDEA: XBRL DOCUMENT

Organization and Nature of Planned Business:

9 Months Ended

Sep. 30, 2016

GENERAL ORGANIZATION AND BUSINESS [Abstract]

Nature of Operations [Text Block]

Note 1 – Organization and Nature of Planned Business:

XML 20 R8.htm IDEA: XBRL DOCUMENT

Going Concern:

9 Months Ended

Sep. 30, 2016

Going Concern [Abstract]

Going Concern [Text Block]

Note 2 – Going Concern:

XML 21 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies:

9 Months Ended

Sep. 30, 2016

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]

Significant Accounting Policies [Text Block]

Note 3 – Summary of Significant Accounting Policies:

Use of Estimates:

Cash and Cash Equivalents:

Property and Equipment:

	September 30,		December 31,
	2016		2015
Property and equipment	$	69,716	$	66,770
Accumulated depreciation		(12,782)		(7,595)
Property and equipment, net	$	56,934	$	59,175

Depreciation expense for the nine months ended September 30, 2016 and 2015 was $5,187 and $4,659, respectively.

Research and Development Costs:

Income Taxes:

Risks and Uncertainties:

Stock Compensation:

Recent Accounting Pronouncements:

XML 22 R10.htm IDEA: XBRL DOCUMENT

Contractual Commitments:

9 Months Ended

Sep. 30, 2016

Contractual Commitments [Abstract]

Contractual Commitments [Text Block]

Note 4 – Contractual Commitments:

XML 23 R11.htm IDEA: XBRL DOCUMENT

Collaborative Agreements:

9 Months Ended

Sep. 30, 2016

Collaborative Agreements [Abstract]

Collaborative Agreements [Text Block]

Note 5 – Collaborative Agreements:

During the nine months ended September 30, 2016, the Company paid Stanford the annual maintenance fee of $10,000 which will be amortized over the applicable one-year licensing period.

Also, in connection with the execution of the Services Agreement, Neurotrope BioScience received consent and entered into a Statement of Work pursuant to its CRE License Agreement (see Note 6 below).

XML 24 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions and Licensing / Research Agreements:

9 Months Ended

Sep. 30, 2016

Note 6 – Related Party Transactions and Licensing / Research Agreements:

XML 25 R13.htm IDEA: XBRL DOCUMENT

Income Taxes:

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note 7 – Income Taxes:

XML 26 R14.htm IDEA: XBRL DOCUMENT

Common Stock:

9 Months Ended

Sep. 30, 2016

STOCKHOLDERS' EQUITY [Abstract]

Stockholders Equity Note Disclosure [Text Block]

Note 8 – Common Stock:

On April 12, 2016, the stockholders of the Company approved to increase the number of authorized shares of our Common Stock to 400,000,000 shares.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

Stock Options:

9 Months Ended

Sep. 30, 2016

Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]

Stock Option Note Disclosure [Text Block]

Note 9 – Stock Options:

The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2016:

					Weighted-
					Average
			Weighted-		Remaining		Aggregate
			Average		Contractual		Intrinsic
	Number of		Exercise		Term		Value
	Shares		Price		(Years)		(in thousands)
Options outstanding at January 1, 2016		8,582,952	$	1.32		7.5	$	0
Options granted		1,400,000	$	0.60
Less options forfeited		(280,418)	$	0.66
Less options expired/cancelled		(20,000)	$	1.76
Less options exercised		-	$	-
Options outstanding at September 30, 2016		9,682,534	$	1.24		7.8	$	0
Options exercisable at September 30, 2016		7,516,318	$	1.36		7.2	$	0

The following is a summary of stock options outstanding under the plans as of September 30, 2016:

							Stock Options
	Stock Options Outstanding						Exercisable
			Weighted Avg.		Weighted Avg.				Weighted Avg.
Range of	Number of		Contractual Life		Exercise		Number of		Exercise
Exercise Prices	Shares		(years)		Price		Shares		Price
$ 0.01 - $ 0.71		1,928,082		9.33	$	0.60		653,130	$	0.61
$ 0.80 - $ 1.00		3,062,048		7.76	$	0.93		2,397,551	$	0.92
$ 1.11 - $ 1.55		1,120,000		7.55	$	1.32		994,411	$	1.29
$ 1.64 - $ 2.22		3,572,404		7.08	$	1.82		3,471,226	$	1.82
		9,682,534		7.80	$	1.36		7,516,318	$	1.39

The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Common and Preferred Stock Reserved for Future Issuances:

9 Months Ended

Sep. 30, 2016

Common And Preferred Stock Reserved For Future Issuances [Abstract]

Common And Preferred Stock Reserved For Future Issuances [Text Block]

Note 10 – Common and Preferred Stock Reserved for Future Issuances:

Common stock reserved for future issuances consisted of the following at September 30, 2016:

	Common
	Stock
	Reserved
Common stock warrants outstanding		134,800,876
Common stock for potential anti-dilution of warrants		66,712,722
Common stock options outstanding		9,682,534
Conversion of Series B Stock		25,692,740
Common stock for potential anti-dilution of Series B Stock		12,846,370
Total		249,735,242

XML 29 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events:

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note 11 – Subsequent Events:

From October 1, 2016 through November 11, 2016, one holder of the Company’s Series B Stock converted a total of 1,477 shares of the Company’s Series B Stock into 144,700 shares of Common Stock.

From October 1, 2016 through November 11, 2016, three holders of 7,371 warrants exercisable at $0.01 per share of Common Stock exercised their warrants into 7,371 shares of Common Stock.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies: (Policies)

9 Months Ended

Sep. 30, 2016

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates:

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents:

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment:

	September 30,		December 31,
	2016		2015
Property and equipment	$	69,716	$	66,770
Accumulated depreciation		(12,782)		(7,595)
Property and equipment, net	$	56,934	$	59,175

Depreciation expense for the nine months ended September 30, 2016 and 2015 was $5,187 and $4,659, respectively.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs:

Income Tax, Policy [Policy Text Block]

Income Taxes:

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Risks and Uncertainties:

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock Compensation:

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements:

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 31 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies: (Tables)

9 Months Ended

Sep. 30, 2016

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]

Property, Plant and Equipment [Table Text Block]

	September 30,		December 31,
	2016		2015
Property and equipment	$	69,716	$	66,770
Accumulated depreciation		(12,782)		(7,595)
Property and equipment, net	$	56,934	$	59,175

XML 32 R20.htm IDEA: XBRL DOCUMENT

Stock Options: (Tables)

9 Months Ended

Sep. 30, 2016

Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of stock option activity under the stock option plans for the nine months ended September 30, 2016:

					Weighted-
					Average
			Weighted-		Remaining		Aggregate
			Average		Contractual		Intrinsic
	Number of		Exercise		Term		Value
	Shares		Price		(Years)		(in thousands)
Options outstanding at January 1, 2016		8,582,952	$	1.32		7.5	$	0
Options granted		1,400,000	$	0.60
Less options forfeited		(280,418)	$	0.66
Less options expired/cancelled		(20,000)	$	1.76
Less options exercised		-	$	-
Options outstanding at September 30, 2016		9,682,534	$	1.24		7.8	$	0
Options exercisable at September 30, 2016		7,516,318	$	1.36		7.2	$	0

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

The following is a summary of stock options outstanding under the plans as of September 30, 2016:

							Stock Options
	Stock Options Outstanding						Exercisable
			Weighted Avg.		Weighted Avg.				Weighted Avg.
Range of	Number of		Contractual Life		Exercise		Number of		Exercise
Exercise Prices	Shares		(years)		Price		Shares		Price
$ 0.01 - $ 0.71		1,928,082		9.33	$	0.60		653,130	$	0.61
$ 0.80 - $ 1.00		3,062,048		7.76	$	0.93		2,397,551	$	0.92
$ 1.11 - $ 1.55		1,120,000		7.55	$	1.32		994,411	$	1.29
$ 1.64 - $ 2.22		3,572,404		7.08	$	1.82		3,471,226	$	1.82
		9,682,534		7.80	$	1.36		7,516,318	$	1.39

XML 33 R21.htm IDEA: XBRL DOCUMENT

Common and Preferred Stock Reserved for Future Issuances: (Tables)

9 Months Ended

Sep. 30, 2016

Common And Preferred Stock Reserved For Future Issuances [Abstract]

Schedule of Guarantor Obligations [Table Text Block]

	Common
	Stock
	Reserved
Common stock warrants outstanding		134,800,876
Common stock for potential anti-dilution of warrants		66,712,722
Common stock options outstanding		9,682,534
Conversion of Series B Stock		25,692,740
Common stock for potential anti-dilution of Series B Stock		12,846,370
Total		249,735,242

XML 34 R22.htm IDEA: XBRL DOCUMENT

Organization and Nature of Planned Business: (Details Textual) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001

XML 35 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies: (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment	$ 69,716	$ 66,770
Accumulated depreciation	(12,782)	(7,595)
Property and equipment, net	$ 56,934	$ 59,175

XML 36 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies: (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Depreciation, Depletion and Amortization	$ 5,187	$ 4,659

XML 37 R25.htm IDEA: XBRL DOCUMENT

Contractual Commitments: (Details Textual)	1 Months Ended	9 Months Ended
Contractual Commitments: (Details Textual)	Aug. 31, 2016 USD ($) shares	Sep. 30, 2016 USD ($)	Sep. 04, 2014 USD ($) ft²
Contractual Commitments And Contingencies [Line Items]
Accrued Rent			$ 88,000
Area of Land \| ft²			4,000
Description of Lessor Leasing Arrangements, Operating Leases		The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options.
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year		$ 136,100
SM Capital Management, LLC [Member]
Contractual Commitments And Contingencies [Line Items]
Management Fee Payable	$ 10,000
Monthly Consulting Fee Installments payable	120,000
Chief Executive Officer [Member]
Contractual Commitments And Contingencies [Line Items]
Supplemental Unemployment Benefits, Severance Benefits	200,000
Management Fee Payable	$ 50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares \| shares	700,055
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Management [Member]
Contractual Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares \| shares	599,596
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Employment Agreements [Member]
Contractual Commitments And Contingencies [Line Items]
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year		70,000
Contractual Obligation, Due in Second Year		$ 210,000

XML 38 R26.htm IDEA: XBRL DOCUMENT

Collaborative Agreements: (Details Textual) - USD ($)				1 Months Ended		9 Months Ended
Collaborative Agreements: (Details Textual) - USD ($)	Nov. 11, 2015	Oct. 09, 2015	May 15, 2014	Jun. 30, 2016	Nov. 19, 2014	Sep. 30, 2016
Collaborative Agreements [Line Items]
Estimated Budget For Services		$ 11,600,000
Payments for Advance to Affiliate	$ 1,875,861	$ 200,000
Service Fees	928,000
Pass Through Expenses	268,000
Investigator And Institute fees	680,000
Research and Development Expense [Member]
Collaborative Agreements [Line Items]
Percentage of Expenses of Total Amount Due						75.00%
January 2016 through September 2017 [Member]
Collaborative Agreements [Line Items]
Estimated Budget For Services	$ 9,500,000
Contract Research Organization [Member]
Collaborative Agreements [Line Items]
Commitment To Pay Fees			$ 715,159	$ 150,000
Reduction Of Commitment Fees					$ 657,238
Payments for Fees				$ 837,112
Worldwide Clinical Trials [Member]
Collaborative Agreements [Line Items]
Prepaid Expense						$ 1,050,000
Stanford Agreement [Member]
Collaborative Agreements [Line Items]
Annual License Maintenance Fee						10,000
Mount Sinai Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee						$ 29,400

XML 39 R27.htm IDEA: XBRL DOCUMENT

Related Party Transactions and Licensing / Research Agreements: (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 12, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Technology Services Costs						$ 2,052,595
Research and Development Expense, Total		$ 1,729,929	$ 268,665	$ 3,548,608	$ 1,348,143
Due to Related Parties, Current		352,624		352,624		$ 389,058
BRNI License Agreement [Member]
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 1,166,666
Service Fees Third Party	$ 83,333
Due to Related Parties		20,000		20,000
November 2015 SOW Agreement [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Purchases from Related Party				750,000
Blanchette Rockefeller Neurosciences Institute [Member]
Related Party Transaction [Line Items]
Royalties Percentage	5.00%
Post PA Fee Proceeds Percent	2.50%
Other Liabilities		$ 348,011		348,011
CRE [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Purchases from Related Party				348,011
Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total				$ 1,000,000
Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalties Percentage				5.00%
Services Reimbursement [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Royalties Percentage				2.00%
Services Reimbursement [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Royalties Percentage				5.00%
Series B Preferred Stock [Member] \| Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 25,000,000
President [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		17.90%		17.90%

XML 40 R28.htm IDEA: XBRL DOCUMENT

Income Taxes: (Details Textual)	47 Months Ended
Income Taxes: (Details Textual)	Sep. 30, 2016 USD ($)
Income Tax Expenses Benefit [Line Items]
Operating Income (Loss)	$ 29,000,000
Deferred Tax Assets, Gross, Current	10,500,000
Deferred Tax Assets, Net	$ 477,000

XML 41 R29.htm IDEA: XBRL DOCUMENT

Common Stock: (Details Textual) - $ / shares	9 Months Ended
Common Stock: (Details Textual) - $ / shares	Sep. 30, 2016	Apr. 12, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Common Stock, Shares Authorized	400,000,000	400,000,000	400,000,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted	5,422
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0001
Neurotrope Inc. [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion	542,200
Warrants Exercisable	27,364
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	27,364
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01

XML 42 R30.htm IDEA: XBRL DOCUMENT

Stock Options: (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Options outstanding	8,582,952
Number of Shares, Options granted	1,400,000
Number of Shares, Less options forfeited	(280,418)
Number of Shares, Less options expired/cancelled	(20,000)
Number of Shares, Less options exercised	0
Number of Shares, Options outstanding	9,682,534	8,582,952
Number of Shares, Options exercisable	7,516,318
Weighted-Average Exercise Price, Options outstanding	$ 1.32
Weighted-Average Exercise Price, Options granted	0.60
Weighted-Average Exercise Price, Less options forfeited	0.66
Weighted-Average Exercise Price, Less options expired/cancelled	1.76
Weighted-Average Exercise Price, Less options exercised	0
Weighted-Average Exercise Price, Options outstanding	1.24	$ 1.32
Weighted-Average Exercise Price, Options exercisable	$ 1.36
Weighted-Average Remaining Contractual Term, Options outstanding (in years)	7 years 9 months 18 days	7 years 6 months
Weighted-Average Remaining Contractual Term, Options exercisable (in years)	7 years 2 months 12 days
Aggregate Intrinsic Value, Options outstanding	$ 0	$ 0
Aggregate Intrinsic Value, Options exercisable	$ 0

XML 43 R31.htm IDEA: XBRL DOCUMENT

Stock Options: (Details 1) - $ / shares	9 Months Ended
Stock Options: (Details 1) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding, Number of Shares	9,682,534	8,582,952
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 2 months 12 days
Weighted Avg. Exercise Price	$ 1.24	$ 1.32
Stock Options Exercisable, Number of Shares	7,516,318
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 1.36
Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.01
Range of Exercise Prices, Upper Range Limit	$ 0.71
Stock Options Outstanding, Number of Shares	1,928,082
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	9 years 3 months 29 days
Weighted Avg. Exercise Price	$ 0.6
Stock Options Exercisable, Number of Shares	653,130
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 0.61
Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.80
Range of Exercise Prices, Upper Range Limit	$ 1.00
Stock Options Outstanding, Number of Shares	3,062,048
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 9 months 4 days
Weighted Avg. Exercise Price	$ 0.93
Stock Options Exercisable, Number of Shares	2,397,551
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 0.92
Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	1.11
Range of Exercise Prices, Upper Range Limit	$ 1.55
Stock Options Outstanding, Number of Shares	1,120,000
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 6 months 18 days
Weighted Avg. Exercise Price	$ 1.32
Stock Options Exercisable, Number of Shares	994,411
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 1.29
Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	1.64
Range of Exercise Prices, Upper Range Limit	$ 2.22
Stock Options Outstanding, Number of Shares	3,572,404
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 29 days
Weighted Avg. Exercise Price	$ 1.82
Stock Options Exercisable, Number of Shares	3,471,226
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 1.82

XML 44 R32.htm IDEA: XBRL DOCUMENT

Stock Options: (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
Stock Options: (Details Textual) - USD ($)	Aug. 31, 2016	Aug. 04, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jul. 23, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					89.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					1.60%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 0.40
Employee Benefits and Share-based Compensation			$ 550,092	$ 142,212	$ 964,779	$ 387,227
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 1,100,000		$ 1,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					2 years 8 months 5 days
Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	599,596
Management [Member] \| Separation Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		1,296,329
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			7,000,000		7,000,000
Equity Incentive Plan 2013 [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							10,000,000
Equity Incentive Plan 2013 [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							3,000,000

XML 45 R33.htm IDEA: XBRL DOCUMENT

Common and Preferred Stock Reserved for Future Issuances: (Details)	Sep. 30, 2016 shares
Class of Stock [Line Items]
Common Stock Reserved	249,735,242
Common stock warrants outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	134,800,876
Common stock for potential anti-dilution of warrants [Member]
Class of Stock [Line Items]
Common Stock Reserved	66,712,722
Common stock options outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	9,682,534
Conversion of Series B Stock [Member]
Class of Stock [Line Items]
Common Stock Reserved	25,692,740
Common stock for potential anti-dilution of Series B Stock [Member]
Class of Stock [Line Items]
Common Stock Reserved	12,846,370

XML 46 R34.htm IDEA: XBRL DOCUMENT

Common and Preferred Stock Reserved for Future Issuances: (Details Textual) - shares		9 Months Ended
	Feb. 09, 2015	Sep. 30, 2016	Sep. 30, 2015
Percentage of shares Reserved for Potential Dilution		50.00%
Conversion of Stock, Shares Issued		244,179	4,002,153
Warrant Holder [Member]
Conversion of Stock, Shares Issued	1,325,000
Series A Preferred Stock [Member] \| Warrant Holder [Member]
Conversion of Stock, Shares Converted	1,325,000

XML 47 R35.htm IDEA: XBRL DOCUMENT

Subsequent Events: (Details Textual) - $ / shares	1 Months Ended	9 Months Ended
Subsequent Events: (Details Textual) - $ / shares	Nov. 11, 2016	Sep. 30, 2016	Sep. 30, 2015
Subsequent Event [Line Items]
Conversion of Stock, Shares Issued		244,179	4,002,153
Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted	1,477
Conversion of Stock, Shares Issued	144,700
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Class of Warrant or Right, Outstanding	7,371
Subsequent Event [Member] \| Warrant [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	7,371

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 83 173 1 false 41 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.neurotropebioscience.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.neurotropebioscience.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.neurotropebioscience.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.neurotropebioscience.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Deficit Sheet http://www.neurotropebioscience.com/role/CondensedConsolidatedStatementOfChangesInShareholdersDeficit Condensed Consolidated Statement of Changes in Shareholders' Deficit Statements 5 false false R6.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.neurotropebioscience.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 107 - Disclosure - Organization and Nature of Planned Business: Sheet http://www.neurotropebioscience.com/role/OrganizationAndNatureOfPlannedBusiness Organization and Nature of Planned Business: Notes 7 false false R8.htm 108 - Disclosure - Going Concern: Sheet http://www.neurotropebioscience.com/role/GoingConcern Going Concern: Notes 8 false false R9.htm 109 - Disclosure - Summary of Significant Accounting Policies: Sheet http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies: Notes 9 false false R10.htm 110 - Disclosure - Contractual Commitments: Sheet http://www.neurotropebioscience.com/role/ContractualCommitments Contractual Commitments: Notes 10 false false R11.htm 111 - Disclosure - Collaborative Agreements: Sheet http://www.neurotropebioscience.com/role/CollaborativeAgreements Collaborative Agreements: Notes 11 false false R12.htm 112 - Disclosure - Related Party Transactions and Licensing / Research Agreements: Sheet http://www.neurotropebioscience.com/role/RelatedPartyTransactionsAndLicensingResearchAgreements Related Party Transactions and Licensing / Research Agreements: Notes 12 false false R13.htm 113 - Disclosure - Income Taxes: Sheet http://www.neurotropebioscience.com/role/IncomeTaxes Income Taxes: Notes 13 false false R14.htm 114 - Disclosure - Common Stock: Sheet http://www.neurotropebioscience.com/role/CommonStock Common Stock: Notes 14 false false R15.htm 115 - Disclosure - Stock Options: Sheet http://www.neurotropebioscience.com/role/StockOptions Stock Options: Notes 15 false false R16.htm 116 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: Sheet http://www.neurotropebioscience.com/role/CommonAndPreferredStockReservedForFutureIssuances Common and Preferred Stock Reserved for Future Issuances: Notes 16 false false R17.htm 117 - Disclosure - Subsequent Events: Sheet http://www.neurotropebioscience.com/role/SubsequentEvents Subsequent Events: Notes 17 false false R18.htm 118 - Disclosure - Summary of Significant Accounting Policies: (Policies) Sheet http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies: (Policies) Policies http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 119 - Disclosure - Summary of Significant Accounting Policies: (Tables) Sheet http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies: (Tables) Tables http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 120 - Disclosure - Stock Options: (Tables) Sheet http://www.neurotropebioscience.com/role/StockOptionsTables Stock Options: (Tables) Tables http://www.neurotropebioscience.com/role/StockOptions 20 false false R21.htm 121 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: (Tables) Sheet http://www.neurotropebioscience.com/role/CommonAndPreferredStockReservedForFutureIssuancesTables Common and Preferred Stock Reserved for Future Issuances: (Tables) Tables http://www.neurotropebioscience.com/role/CommonAndPreferredStockReservedForFutureIssuances 21 false false R22.htm 122 - Disclosure - Organization and Nature of Planned Business: (Details Textual) Sheet http://www.neurotropebioscience.com/role/OrganizationAndNatureOfPlannedBusinessDetailsTextual Organization and Nature of Planned Business: (Details Textual) Details http://www.neurotropebioscience.com/role/OrganizationAndNatureOfPlannedBusiness 22 false false R23.htm 123 - Disclosure - Summary of Significant Accounting Policies: (Details) Sheet http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies: (Details) Details http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 124 - Disclosure - Summary of Significant Accounting Policies: (Details Textual) Sheet http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies: (Details Textual) Details http://www.neurotropebioscience.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 125 - Disclosure - Contractual Commitments: (Details Textual) Sheet http://www.neurotropebioscience.com/role/ContractualCommitmentsDetailsTextual Contractual Commitments: (Details Textual) Details http://www.neurotropebioscience.com/role/ContractualCommitments 25 false false R26.htm 126 - Disclosure - Collaborative Agreements: (Details Textual) Sheet http://www.neurotropebioscience.com/role/CollaborativeAgreementsDetailsTextual Collaborative Agreements: (Details Textual) Details http://www.neurotropebioscience.com/role/CollaborativeAgreements 26 false false R27.htm 127 - Disclosure - Related Party Transactions and Licensing / Research Agreements: (Details Textual) Sheet http://www.neurotropebioscience.com/role/RelatedPartyTransactionsAndLicensingResearchAgreementsDetailsTextual Related Party Transactions and Licensing / Research Agreements: (Details Textual) Details http://www.neurotropebioscience.com/role/RelatedPartyTransactionsAndLicensingResearchAgreements 27 false false R28.htm 128 - Disclosure - Income Taxes: (Details Textual) Sheet http://www.neurotropebioscience.com/role/IncomeTaxesDetailsTextual Income Taxes: (Details Textual) Details http://www.neurotropebioscience.com/role/IncomeTaxes 28 false false R29.htm 129 - Disclosure - Common Stock: (Details Textual) Sheet http://www.neurotropebioscience.com/role/CommonStockDetailsTextual Common Stock: (Details Textual) Details http://www.neurotropebioscience.com/role/CommonStock 29 false false R30.htm 130 - Disclosure - Stock Options: (Details) Sheet http://www.neurotropebioscience.com/role/StockOptionsDetails Stock Options: (Details) Details http://www.neurotropebioscience.com/role/StockOptionsTables 30 false false R31.htm 131 - Disclosure - Stock Options: (Details 1) Sheet http://www.neurotropebioscience.com/role/StockOptionsDetails1 Stock Options: (Details 1) Details http://www.neurotropebioscience.com/role/StockOptionsTables 31 false false R32.htm 132 - Disclosure - Stock Options: (Details Textual) Sheet http://www.neurotropebioscience.com/role/StockOptionsDetailsTextual Stock Options: (Details Textual) Details http://www.neurotropebioscience.com/role/StockOptionsTables 32 false false R33.htm 133 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: (Details) Sheet http://www.neurotropebioscience.com/role/CommonAndPreferredStockReservedForFutureIssuancesDetails Common and Preferred Stock Reserved for Future Issuances: (Details) Details http://www.neurotropebioscience.com/role/CommonAndPreferredStockReservedForFutureIssuancesTables 33 false false R34.htm 134 - Disclosure - Common and Preferred Stock Reserved for Future Issuances: (Details Textual) Sheet http://www.neurotropebioscience.com/role/CommonAndPreferredStockReservedForFutureIssuancesDetailsTextual Common and Preferred Stock Reserved for Future Issuances: (Details Textual) Details http://www.neurotropebioscience.com/role/CommonAndPreferredStockReservedForFutureIssuancesTables 34 false false R35.htm 135 - Disclosure - Subsequent Events: (Details Textual) Sheet http://www.neurotropebioscience.com/role/SubsequentEventsDetailsTextual Subsequent Events: (Details Textual) Details http://www.neurotropebioscience.com/role/SubsequentEvents 35 false false All Reports Book All Reports ntrp-20160930.xml ntrp-20160930.xsd ntrp-20160930_cal.xml ntrp-20160930_def.xml ntrp-20160930_lab.xml ntrp-20160930_pre.xml true true ZIP 54 0001144204-16-134253-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-134253-xbrl.zip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즏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